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ABSTRACT 
Polycyclic aromatic hydrocarbons (PAH) are important environmental pollutants 
generally formed during incomplete combustion of organic matter containing carbon and 
hydrogen. Introduced into the human body by adsorption through the skin, ingestion or 
inhalation, the biotransformation processes of PAH lead to the formation of multiple metabolites. 
Due to the short elimination lifetime from the body, the quantitative determination of 
monohydroxy-PAH (OH-PAH) in urine samples provides accurate information on recent 
exposure to environmental PAH. Urine analysis of OH-PAH with established methodology relies 
on sample clean-up and pre-concentration followed by chromatographic separation and 
quantification. Although chromatographic techniques provide reliable results in the analysis of 
OH-PAH, their experimental procedures are time consuming and expensive. Additional problems 
arise when laboratory procedures are scaled up to handle thousands of samples under mass 
screening conditions. Under the prospective of a sustainable environment, the large usage of 
organic solvents is one of the main limitations of current chromatographic methodology. It is 
within this context that new analytical approaches based on easy-to-use and cost-effective 
methodology become extremely relevant. This dissertation focuses on the development of 
screening methodology for the routine analysis of PAH metabolites in numerous samples. It 
explores the room-temperature fluorescence properties of six metabolites originating from parent 
PAH included in the Environmental Protection Agency priority pollutants list. 1-
hydroxyfluorene, 1-hydroxypyrene, 6-hydroxychrysene, 9-hydroxyphenanthrene, 3-
hydroxybenzo[a]pyrene and 4-hydroxybenzo[a]pyrene are used as model biomarkers to 
investigate the analytical potential of new methods based on solid-phase extraction (SPE) and 
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room-temperature fluorescence (RTF) spectroscopy. Quantitative determination of metabolites is 
carried out either in the eluent extract[1, 2] or on the surface of extraction membranes[3, 4]. The 
direct determination – i.e., no chromatographic separation - of the six metabolites is based on the 
collection of excitation-emission matrices and synchronous fluorescence spectra.  
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CHAPTER 1: GENERAL INTRODUCTION 
1.1 Polycyclic Aromatic Hydrocarbons  
Polycyclic aromatic hydrocarbons (PAH) are important environmental pollutants 
originating from a wide variety of natural and anthropogenic sources. PAH are generally formed 
during incomplete combustion of organic matter containing carbon and hydrogen.[5-15] Due to the 
carcinogenic nature of some PAH, their chemical analysis is of great environmental and 
toxicological importance. Among the hundreds of PAH present in the environment, the EPA lists 
the following sixteen as "Consent Decree" priority pollutants: benz[a]anthracene, 
benzo[b]fluoranthene, benzo[k]fluoranthene, benzo[a]pyrene, dibenzo[a,h]anthracene, 
indeno[1,2,3-cd]pyrene, naphthalene, acenaphthylene, acenaphthene, fluorene, phenanthrene, 
anthracene, fluoranthene, pyrene, chrysene, and benzo[g,h,i]perylene. Their molecular structures 
are shown in Figure 1.1. According to the EPA, these PAH should be routinely monitored to 
avoid human exposure to contaminated sites.   
Human exposure to PAH derives from a variety of sources such as air pollution from 
automobile, diesel and industrial or incinerator emissions, which may modulate a spectrum of 
their other combustion, dietary and occupational sources. The primary source of PAH exposure 
in humans is through food consumption.[16, 17] Cereal and vegetables are the major dietary 
sources of PAH, except when there is a high consumption of meat cooked over an open flame.[18] 
More than 150 PAH have been found in tobacco smoke,[19] which also contributes significantly 
to exposure to PAH[20] and to adverse health effects.[21]  
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Figure 1.1  Molecular structures of 16 EPA PAH. 
 
A less pervasive source of air pollution leading to PAH exposure involves biomass 
burning from forest fires and peat bogs resulting from incidental incineration, or from deliberate 
forest cleaning strategies that expend beyond planned boundaries.[18] Wood combustion as an 
energy source for heating and/or cooking also generates a source of indoor PAH pollution 
  
 
 
Naphthalene Fluorene dibenz[a,h]anthracene pyrene 
  
 
 
Acenaphthene fluoranthene chrysene anthracene 
   
 
acenaphthylene benzo[g,h,i]perylene benzo[a]anthracene benzo[k]fluoranthene 
  
  
Phenanthrene benzo[b]fluoranthene indeno[1,2,3-cd]pyrene benzo[a]pyrene 
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leading to health problems.[22, 23] Occupational exposures may result from daily contact with 
intensive combustion processes such as iron and steel production,[24] coke production,[25] waste 
incinerators,[26] transportation maintenance,[27] mining exhaust exposure[28] and aluminum 
smelters,[29] or from tobacco smoke in commercial venues[21] such as bars, restaurants and 
nightclubs. More intensive PAH exposures in occupational environments – relative to the general 
population – have resulted in reports of lung, genitourinary and skin cancers.[30]  
1.2   Metabolites of Polycyclic Aromatic Hydrocarbons 
Although environmental monitoring of PAH is an important step to prevent exposure to 
contaminated sites, it provides little information on the actual uptake and subsequent risks. PAH 
are introduced in the body by adsorption through the skin, ingestion or inhalation and can be 
subsequently metabolized to their more polar metabolites.  The biotransformation process 
consists of two phases. In phase I metabolism, PAH are oxidized by the cytochrome P450 
enzymes to form reactive epoxide intermediates, followed by reduction or hydrolysis to 
hydroxylated derivatives. In phase II metabolism, hydroxyl-PAH form glucoronate and sulfate 
conjugates to facilitate their excretion through urine, bile and feces.[31]  These biological 
processes lead to the formation of multiple metabolites including epoxide, dihydrodiols, 
monohydroxylated-PAH (OH-PAH) and polyhydroxy-PAH. Covalent binding to DNA is 
believed to be the first critical step in the initiation of the tumor formation process. [32, 33] This is 
depicted in Figure 1.2 which shows the metabolic pathways of benzo[a]pyrene (B[a]P), which is 
the most carcinogenic compound in the EPA priority pollutants list. [34]  The metabolic pathways 
of B[a]P include the formation of diol epoxides and their subsequent binding to DNA to form the 
PAH-DNA adducts. These adducts can then be repaired, restoring the original healthy DNA, or 
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they can originate mutant DNA leading to the formation and proliferation of tumors.    
 
 
  Figure 1.2  Overview of B[a]P metabolism. CYP: Cytochrome P450. Adapted from 
[31]
.  
  
Due to the short average lifetime of OH-PAH elimination from the body, their 
quantitative determination in biological fluids such as urine and blood samples provides accurate 
information on recent exposure to environmental PAH.[35]  Early methods[35-37] for the analysis of 
urine samples focused on a few OH-PAH, with particular emphasis on 1-hydroxypyrene.[36] 
Considering that human exposure often occurs to complex mixtures with numerous PAH, recent 
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methods have expanded their scope to a larger number of metabolites. [1, 38] Particular attention 
has been paid to metabolites resulting from exposure to EPA-PAH, i.e. PAH included in the EPA 
priority pollutants list.  
1.3   Urine analysis of OH-PAH 
The general trend for the analysis of OH-PAH in urine samples follows the pattern of 
sample collection and hydrolysis, sample clean-up and pre-concentration, and chromatographic 
separation and quantification. The hydrolysis step – which can be either enzymatic or acidic – 
dissociates OH-PAH from their glucuronide and/or sulfate conjugates.[1] Popular approaches for 
sample clean-up and pre-concentration include liquid-liquid extraction (LLE)[39] and SPE[40].   
Both methodologies are well suited to automation, which increases sample throughput and 
reduces variability due to manual sample handling. Chromatographic separation and 
quantification has been based on high-performance liquid chromatography-room temperature 
fluorescence detection (HPLC)[41-43] and gas chromatography-mass spectrometry (GC-MS). [44-47] 
Table 1.1 summarizes several features of previously reported methods for the chromatographic 
analysis of OH-PAH in urine samples. The tabulated information only includes five of the six the 
metabolites investigated in this dissertation, namely 2-hydroxyfluorene (2OH-Flu), 1-
hydroxypyrene (1OH-Pyr), 9-hydroxyphenanthrene (9OH-Phen), 6-hydroxyxhrysene (6OH-
Chry), 3-hydroxybenzo[a]pyrene (3OH-B[a]P). No reports were found on the analysis of 4-
hydroxybenzo[a]pyrene (4OH-B[a]P) in urine samples.  
Numerous HPLC and GC-MS methods have been published for the analysis of OH-PAH 
metabolites in urine samples. Interesting to note is the wide range of recoveries reported for the 
metabolites under investigation.  Unfortunately, the standard deviations of the analytical 
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recoveries were not reported, which make difficult the statistical comparison of the observed 
differences in their average values. Comparison of the analytical recoveries for those metabolites 
with reported values via the two methods reveals better recoveries via GC-MS for 2OH-Flu. 
9OH-Phen and 1OH-Pyr presented approximately the same recovery via HPLC and GC analysis. 
The best limits of detection (LOD) were clearly obtained via GCMS. Unfortunately GC-MS 
procedures are more complicated than HPLC methodology.[38, 45] GC-MS requires a chemical 
derivatization step prior to metabolite separation to avoid peak tailing in the chromatographic 
column.  
1.4  Overall goal of this dissertation 
Although chromatographic techniques provide reliable results in the analysis of OH-PAH, 
their experimental procedures are time consuming and expensive. Elution times of 30-60 minutes 
are typical and standards must be run periodically to verify retention times. If the concentrations 
of target species are found to lie outside the detector’s response range, the sample must be 
diluted and the process repeated. On the other end of the concentration range, many samples are 
“zeroes,” i.e. the concentrations are below detection limits. Additional problems arise when 
laboratory procedures are scaled up to handle thousands of samples under mass screening 
conditions. Under the prospective of a sustainable environment, the large usage of organic 
solvents is one of the main limitations of the current chromatographic methodology.   
It is within this context that new analytical approaches based on easy-to-use and cost-
effective methodology that provide large sample throughput become extremely relevant.  The 
research presented here focuses on the development of screening methodology for the routine 
analysis of PAH metabolites in numerous samples. It explores the room-temperature 
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fluorescence properties of 2OH-Flu, 1OH-Pyr, 9OH-Phen, 6OH-Chry, 3OH-B[a]P and 4OH-
B[a]P. These metabolites are used as model biomarkers to investigate the analytical potential of 
simple methods based on SPE and Room-Temperature Fluorescence spectroscopy (SPE-RTF). 
The remaining of this chapter is then devoted to cover basic principles of SPE, fluorescence 
spectroscopy, excitation-emission matrices (EEMs), synchronous fluorescence spectroscopy 
(SFS) and data analysis techniques.  
SPE of OH-PAH is usually carried out with the aid of non-polar sorbents such as 
octadecyl-silica particles. The effectiveness of octadecyl-silica sorbents is based on the same 
sorption-desorption phenomena as in reversed-phase liquid chromatography. The main 
mechanism of OH-PAH isolation is a non-polar interaction, i.e. Van der Waals forces. OH-PAH 
will pass into the solid surface, and given time, the equilibrium will be established between the 
two phases. The equilibrium for each OH-PAH is described by its partition coefficient, which is 
simply the ratio of OH-PAH concentrations in the two phases. The driving force for the partition 
mechanism results from the difference in the chemical potential of the metabolite in the solid 
(sorbent) and the liquid phase (aqueous sample). The chemical potential equation of any given 
metabolite (OH-PAHi) in any given phase (p) is given by: 
     μi
p
 = (μ0)i
p
 + RTInCi                                       (1.1) 
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      Table 1.1  Analytical figures of merit reported for OH-PAH analysis in urine samples by HPLC and GC-MS 
Metabolite 
LOD 
(ng/mL) 
Recovery  
(%) 
Sample Preparation 
Instrumental 
method 
Analysis time 
(min)a 
Reference 
2-hydroxyfluorene 727 62 SPE, evap. HPLC 40 [43] 
2-hydroxyfluorene 3.6 82 SPE, evap., derivatization GC-MS 27 [45] 
9-hydroxyphenanthrene 165 57 SPE, evap. HPLC 40 [43] 
9-hydroxyphenanthrene 200 50 SPE, evap., derivatization GC-MS 40 [46] 
1-hydroxypyrene 40 83 SPE, evap. HPLC 40 [43] 
1-hydroxypyrene 44 68 SPE, evap. HPLC 40 [43] 
1-hydroxypyrene 1.6 99 SPE, evap., derivatization GC-MS 24 [34] 
1-hydroxypyrene 3.3 80 SPE, evap., derivatization GC-MS 27 [45] 
3-hydroxybenzo[a]pyrene 1615 40 SPE, evap. HPLC 40             [43] 
3-hydroxybenzo[a]pyrene 40 48 SPE, evap. HPLC 45 [48] 
3-hydroxybenzo[a]pyrene 10.0 NA SPE, evap., derivatization GC-MS 27 [42] 
6-hydroxychrysene 1.7 68 SPE,evap. HPLC 23 [49]     
        aInstrumental analysis only; does not include sample preparation procedures 
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where μi
p is the chemical potential of OH-PAHi in phase “p”, (μ
0)i
p is the standard 
chemical potential of OH-PAHi in phase “p”, and Ci is the OH-PAHi concentration in phase “p”. 
When equilibrium is established, the chemical potential of OH-PAHi in the sorbent (s) and 
aqueous (a) phases reaches the same value, i.e.:  
     μi
s
 = μi
a
                                                            (1.2) 
The concentration of OH-PAHi in each phase depends on its partition coefficient. The 
larger the partition coefficient the better the retention of OH-PAHi will be in the solid phase. The 
partition coefficient or capacity factor (K) can be represented by 
     Ci
s
/Ci
a
 = exp[ -Δμ0i / RT]                                           (1.3) 
     K = Ci
s
/Ci
a
                                                        (1.4) 
SPE materials are packed in two formats, discs and cartridges. A SPE cartridge consists 
of a small column (generally an open syringe barrel) containing a sorbent with an average 
particle size of about 40 packed between plastic frits. The sorbent bed occupies about one-third 
of the syringe barrel volume. The remaining volume is used as sample reservoir. SPE discs are 
particle-loaded membranes in the form of flexible discs of various diameters and 0.5-1.0 mm of 
thickness. They are packed in a way that the sorbent is enmeshed into a web of some other inert 
polymer, e.g., Teflon, or is trapped in a glass fiber or paper filter. SPE discs are preferred over 
cartridges because their larger cross-sectional area and shorter bed depth allow higher flow rates 
and shorter analysis time.  
The experimental procedure for SPE consists of four steps: conditioning, retention, 
rinsing and drying. The solid sorbent must undergo proper conditioning to wet the packing 
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material before the sample passes through the SPE device. In its dry form, the octadecyl (C18) 
bonded-phase material is randomly oriented on the surface. If the sorbent is placed in contact 
with an aqueous sample, the environment surrounding the bonded organic moiety would be 
highly polar and entirely incompatible with a C18 bonded-phase. The bonded groups try to 
minimize the exposure to the high polarity medium by forming clusters among them that are 
close to each other. In such a configuration, the organic surface that is exposed to the solute is 
very small. This arrangement of the bonded organic groups diminishes the extraction efficiency 
of SPE. The conditioning step “activates” the sorbent by treatment with an organic solvent, 
typically methanol. Under these conditions, the bonded-organic moiety is more open and 
available for interaction with the solute. This process can be determined as one of the most 
important steps for a successful SPE.  
After conditioning, the sample is loaded to the SPE device by gravity feed, pumping, or 
vacuum. Depending on the type of sample, micro-liters to liters of liquid sample can be applied 
through the sorbent phase. During this step, OH-PAH are extracted and pre-concentrated in the 
solid sorbent. Some of the matrix concomitants may also be retained along with OH-PAH, 
making matrix composition more challenging for further OH-PAH analysis.  
 A rinsing step is then used to remove potential interferences from the SPE material. For 
aqueous samples, a water-organic-solvent mixture is usually used as the rinsing solvent. The 
final step is the elution of OH-PAH from the sorbent with an appropriate solvent specifically 
chosen to disrupt the metabolite-sorbent interaction. The elution solvent should remove as little 
as possible of the other substances sorbed on the column.  
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Tables 1.2 and Table 1.3 summarize the typical composition of human urine samples. The 
molecular structures of the major components are shown in Appendix A in this dissertation.  
Urea, sodium and potassium salts are very soluble in water and should not be retained by C18 
silica sorbents. The same is not true for creatinine and ammonium salts – such as ammonium 
hippurate – which could be retained by the sorbent and co-eluted with OH-PAH. In addition to 
the potential interference of common urine components, the analyst should keep in mind the 
chemical variations that occur due to internal and external factors [50].  Internal factors include 
body temperature, pressure and mental state of the individual that can lead to the production or 
breakdown of different metabolites in any given period.  The same is true for external factors 
such as food, drug intake, and environmental contamination due to inhalation or skin contact. 
These include compounds with low solubility in water such as vitamins, phenolic compounds, 
and anti-inflammatory, antibiotic and antipyretic drugs [51-55].   
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Table 1.2  Composition of typical human urine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from [56] 
 
 
 
 
Item Formula 
Inorganic Salts  
Sodium Chloride NaCl 
Potassium Chloride KCl 
Potassium Sulfate K2SO4 
Magnesium Sulfate MgSO4 
Magnesium Carbonate MgCO3 
Potassium Bicarbonate KHCO3 
Potassium Phosphate K3PO4 
Calcium Phosphate Ca3(PO4)2 
UREA H2NCONH2 
Organic Compounds  
Creatinine C4H7N3O 
Uropepsin (as Tyrosine) HO.C6H4.C2H3(NH2).CO2H 
Creatine HN:C(NH2)N(CH3).CH2.CO2H.H2O 
Glycine NH2.CH2.CO2H 
Phenol C6H5.OH 
Histidine C3H3N2.CH2.CH.(NH2).CO2H 
Androsterone C19H30O2 
Glucose C6H7O6(COCH3)5 
Taurine NH2.CH2.CH2.SO3H 
Organic Ammonium salts  
Hippurate NH4C6H5CO.NHCH2.CO2 
Citrate (NH4)2HC6H5O7 
Glucuronate NH4C6H9O7 
Urate (NH4)2C5H3O3N4 
Lactate (NH4)2C3H5O3 
Asparate NH4C4H6O4N 
Formate (NH4)2.HCO2 
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     Table 1.3    Major Constituents of Human Urine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
    
 
    Adapted from [56] 
 
 
 
 
 
Item 
Range 
Min ( mg/L) Max ( mg/L) 
Total Solutes 36,700 46,700 
Urea 9,300 23,300 
Chloride 1,870 8,400 
Sodium 1,170 4.390 
Potassium 750 2,610 
Creatinine 670 2.150 
Sulfur, Inorganic 163 1,800 
Hippuric Acid 50 1,67.0 
Phosphorus, Total 410 1,070 
Citric Acid 90 930 
Glucuronic Acid 70 880 
Ammonia 200 730 
Uric Acid 40 670 
Uropepsin(as Tyrosine) 70 560 
Bicarbonate 20 560 
Creatine 0 530 
Sulfur, Organic 77 470 
Glycine 90 450 
Phenol 130 420 
Lactic Acid 30 400 
Calcium 30 390 
Histidine 40 330 
Glutamic Acid <7 320 
Androsterone 2 280 
Magnedum 30 260 
Glucose 90 200 
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For efficient retention on the SPE substrate, one would desire the capacity factor of the 
metabolite to be very large in aqueous urine solutions. Similarly, the capacity factor should 
approach zero in 100% organic eluting solvent unless non-reversed-phase interactions were 
taking place. Unfortunately, non-reversed-phase interactions in C18 sorbent materials result from 
the existence of residual silanol groups on the surface of silica particles. These groups, which 
interact with OH-PAH through both hydrogen bonding and dipole-dipole interactions, make 
difficult OH-PAH desorption for subsequent chromatographic analysis. The large variations 
observed for the recoveries of individual OH-PAH in Table 1.1 can be partially attributed to the 
difficulty of metabolite desorption from C18 sorbents. Although previously reported data on the 
standard deviations of average recoveries of individual OH-PAH is scarce and incomplete, the 
reported values show relatively high standard deviations that affect both the precision and the 
accuracy of analysis. It is within this context that development of new SPE approaches and 
instrumental methods become relevant to the analysis of OH-PAH in urine samples.  
1.5   Fluorescence Spectroscopy 
Photoluminescence spectroscopy is based on the detection of radiation of 200-700 nm 
emitted during the deactivation of electronically excited molecules.[57-59]  Under normal 
conditions, the orbital of lowest energy of an organic molecule are occupied by pairs of electrons 
with spin in opposite directions.[60] Since most of the organic molecules have an even number of 
valence electrons, the resulting electron spin is zero. Such a state, with no net spin, is called a 
singlet state. The singlet state of lowest energy is known as the ground state, and it is represented 
in the Jablonski diagram[61] of Figure 1.3 by S0. 
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Through the absorption of electromagnetic radiation (A), a molecule can pass from the 
ground state to an excited state of higher energy. This transition occurs in approximately 10-15 s 
and entails the promotion of an electron from the highest occupied orbital to a previously 
unoccupied one. If the transition occurs with no change in the spin of the promoted electron, the 
excited state will have two unpaired electrons with anti-parallel spins and, therefore, net spin 
equal to zero. An electronic state with these characteristics is known as a singlet excited state. In 
Figure 1.3, the first and second singlet-excited states are represented by S1 and S2, respectively. 
If the transition involves a change in the electronic spin, the excited state will be characterized by 
two unpaired electrons with parallel spins. In this case, the resultant spin is one, and the excited 
state receives the name of triplet state. In Figure 1.3, the triplet state of the lowest energy is 
symbolized by T1 while any other triplet state of higher energy is represented by Tn. 
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Figure 1.3 Jablonski diagram. A is the absorption, F is the fluorescence, P is the 
phosphorescence, VR is the vibrational relaxation, IC is the internal conversion, and ISC is 
the intersystem crossing. 
 
From the S1 state, deactivation of the molecule may happen through various processes. 
External conversion (EC) is a non-radiative deactivation process in which the excited molecule 
transfers its excess electronic energy to surrounding molecules or solvent molecules through 
collisions. From the lowest vibrational level of S1, the molecule may also release the excess of 
electronic energy in the form of a photon. This process is known as fluorescence (F) and it 
occurs on the order of 10-10 to 10-6s. Since IC and VR are comparatively rapid process, 
fluorescence most often occurs from the ground vibrational lever of the first excited single state 
and is of a longer wavelength than absorption. Fluorescence from the S2 state is rare and will 
only occur if the energy gap between the S1 and S2 states is large enough that IC is not favored.  
E
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The S1 state may also be deactivated by a non-radiative process called inter-system 
crossing (ISC). This process involves a crossover of electronic states similar to IC but it occurs 
between states of different spin multiplicity. Population of the upper vibrational levels of the 
triplet state manifold is followed by VR and IC into the ground vibrational level of the first 
triplet excited state (T1). Deactivation of T1 via the emission of a photon is called 
phosphorescence (P) and it occurs on the order of 10-3 to 103 s. Since phosphorescence occurs on 
a relatively long time scale, T1 is particularly susceptible to collisional deactivations. 
[62]  Non-
radiative deactivation of T1, or quenching, can be a particular problem in the presence of oxygen. 
Molecular oxygen resides naturally in a ground triplet configuration possessing two low-lying 
singlet states with excitation energies of approximately 23 and 38 kcal/mol. Any species having 
excitation energy as low as 23 kcal/mol may be quenched by oxygen via energy transfer. Excited 
singlet states may also be affected by oxygen, but since oxygen quenching is diffusion 
controlled, a high oxygen concentration is necessary to quench the relatively short-lived excited 
singlet state. The removal of oxygen is often accomplished through de-oxygenation of sample 
solution or purging the sample compartment with inert gasses. Similar to phosphorescence, 
fluorescence is always in competition with the various non-radiative deactivation processes of 
the excited state. As a result, fluorescence and phosphorescence intensities intrinsically depend 
on the relative efficiencies of all competing processes affecting their respective excited states. 
The efficiencies of fluorescence and phosphorescence are often expressed in terms of quantum 
yield ( ).  
The quantum yield for fluorescence, F , is the ratio of the rate of fluorescence with the 
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rate of absorption, ΦF/ФA, where ΦF = kFnS1V and ФA = kAnS0V. V is the volume of sample 
illuminated; nSx.is the number of molecules occupying the given electronic state x; and kF and kA 
are the rate of fluorescence and absorption, respectively. Under steady state conditions, we can 
assume that nS1 = nS0kA/ (kF + knr), where knr is the sum of rates for the non-radiative processes 
(external conversion, kec; internal conversion, kic; and inter-system crossing, kisc). Using these 
relationships, the fluorescence quantum yield in terms of the rates of the various activation and 
deactivation processes is given by equation (1.5): 
   
nrF
F
F
kk
k

                          (1.5)        
which shows that, in order to improve the fluorescence quantum yield, and hence the 
fluorescence intensity, one needs to minimize the rate contributions from non-radiative 
processes .A similar situation arises for phosphorescence. The phosphorescence quantum yield 
( P ) can be expressed as: 
    
nrP
P
nrFisc
isc
P
kk
k
kkk
k



                                  (1.6)             
  
Note that the first term in equation (1.6) takes into account the efficiency of Inter-system 
crossing. Therefore, to maximize the phosphorescence efficiency, hence the phosphorescence 
intensity, minimization of both non-radiative processes and fluorescence relative to inter-system 
crossing becomes evident. 
The detection of luminescence (fluorescence and/or phosphorescence) is the basis of 
several photoluminescence techniques. Fluorescent and/or phosphorescent compounds usually 
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consist of molecules with extensive  electron systems. These include a large variety of aromatic 
molecules either with or without hetero-atoms in the conjugated system. [58-60, 63] The free 
movement of electrons throughout the delocalized molecular orbitals facilitates the electronic 
transitions responsible for fluorescence and phosphorescence. For molecules with no hetero-
atoms in the aromatic system, transitions frequently involve the promotion of an electron from a 
bonding orbital to an anti-bonding orbital (transition). Aliphatic molecules, on the 
other end, rarely exhibit luminescence since the high energy required for  transitions 
usually causes decomposition prior to excitation. [58-60, 63] 
Among the numerous photoluminescence techniques known in the analytical field, RTF 
spectroscopy is the most popular. RTF offer the advantages of relatively inexpensive 
instrumentation, calibration curves with excellent linear dynamic ranges and appropriate limits of 
detection. In most cases, de-oxygenation of the sample is not critical and fluorescence 
measurements are rapidly performed by placing a quartz cell in the sample compartment of a 
spectrofluorimeter. Conventional fluorometric methods - in which either the excitation or the 
emission wavelength is set at its maximum position while the other is scanned – present limited 
selectivity. The similarity and/or overlapping of broad fluorescence bands at room-temperature 
usually interfere in the characterization of targeted compounds without previous separation.  
Several strategies exist to improve the selectivity of RTF measurements. These include EEMs 
data formats[64, 65] and SFS[66-68].  
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1.6  Excitation-Emission Matrices (EEMs) 
The most popular data format in fluorescence spectroscopy is a two-dimensional (2D) plot 
correlating fluorescence intensities to emission wavelengths. The usual procedure for recording 
2D fluorescence spectra consists of measuring the emission spectrum at a fixed excitation 
wavelength. Similarly, 2D excitation spectra are recorded by monitoring the excitation 
wavelength at a fixed fluorescence wavelength. In most cases, the fluorescence spectral profile 
of a pure compound is independent of the excitation wavelength. The same is true for its 
excitation spectral profile, which remains the same independent of the monitored emission 
wavelength. Maximum fluorescence intensity is always obtained at the maximum excitation 
wavelength of the fluorophor.  
Recording a 2D fluorescence spectrum from a mixture with numerous fluorescence 
components only provides partial information on the total fluorescence of the mixture. The 
emission profile of a mixture with numerous fluorescence components varies with the relative 
positions of the excitation wavelength and the excitation maxima of the fluorophors in the 
mixture. Individual fluorophor contributions to the total fluorescence spectrum of the sample 
also depend on the fluorescence quantum yields of the fluorophors and possible quenching due to 
synergistic effects. For a sample of unknown composition, therefore, variations in the 
fluorescence profile with variations in the excitation wavelength suggest that more than 
fluorescence compound is present in the sample. A similar statement could be made from 
variations in its excitation profile with the monitored emission wavelengths.  
The total fluorescence of the sample, which includes possible quenching and synergistic 
effects, can be gathered in a single data format known as excitation-emission matrix (EEM)[69, 70]. 
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The experimental procedure for collecting EEMs is rather simple. It consists of recording 
fluorescence spectra at various excitation wavelengths. The resulting I by J data matrix (EEM) is 
compiled from an array of 2D fluorescence spectra while the excitation wavelength is increased 
incrementally between each scan[71, 72]. Each I row in the EEM corresponds to the emission 
spectrum at the ith excitation wavelength. Each J column in the EEM corresponds to the 
excitation spectrum at the jth emission wavelength.  For a single emitting species in a sample, the 
elements of the EEM are given by: 
    Mij = 2.303ΦF I0(λi)ε(λi)bcγ(λj)κ(λj)                        (1.7) 
where I0(λi) is the intensity of the incident light exciting the sample in units of quanta/s; 
2.303ε(λi)bc represents the optical density of the sample, which results from the product of the 
analyte’s molar  absorptivity ε(λi), the optical path-length b, and the concentration of the emitting 
species c; ΦF is the quantum yield of fluorescence; γ(λj) is the fraction of fluorescence photons 
emitted at wavelength λj and κ(λj) is an instrumental factor that represents the wavelength 
dependence of the spectrofluorimeter’s sensitivity[71]. The condensed version of equation (1.7) 
may be expressed as:  
      Mij = αxiyj                          (1.8) 
where α = 2.303ΦFbc is a wavelength independent factor containing all of the 
concentration dependence, xi = I0(λi)ε(λi) and yi = γ(λj)κ(λj). The observed relative fluorescence 
excitation spectrum may be represented by xi, the wavelength sequenced set, and thought of as a 
column vector, x in λi space.  The wavelength sequenced set, yi, may be thought of as a row 
vector y in λi space, representing the observed fluorescence emission spectrum.  Therefore, for a 
single component, M is simply represented as: 
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     M = αxy                      (1.9) 
Where M is the product of the vectors x and y multiplied by the compound specific 
parameter α. When data is taken from a sample containing multiple, r, different species, M is 
given by the following expression: 
       ∑    
                           (1.10) 
where k is used to detail the species. For a recorded M, the spectral characterization of 
single components then relies on finding r, αk, x
k, and yk.  
Figure 1.4 and Figure 1.5 provides a schematic representation of an EEM of a compound 
obeying Kasha’s rule[73].  The 2D excitation and fluorescence spectra are depicted along the sides 
of the EEM plot. Within the defined contour levels, this pure compound adheres to the two 
properties of excitation and emission previously discussed, i.e. its fluorescence profile does not 
change with the excitation wavelength and vice-versa. As always observed from an EEM of a 
pure compound, the center of the contour plot corresponds to the maximum excitation and 
emission wavelengths of the fluorophor.  
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Figure 1.4   Contour map of EEM of 3.5ppb 1OH-Pyr on C18 membrane adpated from 
Chapter 3 of this dissertation. 
 
 
Figure 1.5  Color map surface of EEM of 3.5ppb 1OH-Pyr on C18 membrane adpated from 
Chapter 3 of this dissertation. 
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Figure 1.6 provides an example of a more complex EEM recorded from a multicomponent 
fluorescence mixture. Evidence of the multicomponent nature of the EEM becomes clear with 
the multiple changes of the emission profile due to variations in the excitation wavelength. The 
same is true for the variations in excitation spectra with emission wavelengths. The number of 
changes noted in the emission or excitation profiles provides visual indication of the number of 
fluorescence components in the mixture.  
 
220 240 260 280 300 320
320
340
360
380
400
420
440
460
480
E
m
is
s
io
n
 w
a
v
e
le
n
g
th
 (
n
m
)
Excitation wavelength (nm)
 
Figure 1.6 Contour plot of an EEM of a four - component mixture of polycyclic aromatic 
compounds namely 2OH-Flu, 1OH-Pyr, 9OH-Phen, and 3OH-B[a]P on C18 membrane 
adpav ted from Chapter 3 of this dissertation. 
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1.7   Synchronous Fluorescence Spectroscopy  
Conventional fluorescence spectra - in which either the excitation or the emission 
wavelength is set at its maximum position while the other is scanned – present limited selectivity. 
The similarity and/or overlapping of broad fluorescence bands at room temperature usually 
interfere in the characterization of targeted compounds without previous separation. Several 
strategies exist to improve the selectivity of room temperature fluorescence measurements. The 
one employed here is known as synchronous fluorescence spectroscopy (SFS). The synchronous 
excitation approach consists of varying simultaneously both the excitation (0) and emission () 
wavelengths while keeping constant a wavelength interval (0) between them. The 
judicious choice of the  parameter often leads to spectral simplification and resolution of 
spectral overlapping. An example of spectral simplification due to the judicious choise of 
wavelength interval is shown in Figure 1.7, which compares the exitation and flurescence spectra 
of perylene (top) to synchronous fluorescence spectra recorded at two values (bottom). The 
synchronous fluorescence spectrum obtained with a  = 10nm consists of a single emission 
peak. The 30nm wavelength difference results in two emission peaks. In the analysis of a 
complex mixture without previous chromatographic separation, the direct determination of 
perylene with a= 10nm should be less prone to spectral overlapping than its determination 
with a = 30nm. This spectral simplification usually improves the selectivity of the technique 
for multicomponent analysis.[68, 74]  
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Figure 1.7 Excitation and fluorescence spectra (top) and SFS (bottom) of perylene. Adapted 
from 
[74]
 
1.8  Chemometric Algorithms for Background Correction  
Baseline reduction/correction is the process of eliminating "background noise" and/or 
background signal. The effect of baseline differs from spectrum to spectrum.    In spectroscopic 
techniques, it is not unusual to encounter a non-smooth or non-zero baseline.  The simplest kind 
of baseline correction is where the spectrum to be corrected must lay or start on the line where 
there is a zero signal. This can be done by calculating the average signal over the spectral region 
for each spectrum and subtract it from each wavelength in the respective spectrum. Alternatively, 
background correction procedures can be applied for more complicated spectrum. If the 
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background signal is curved and multiple peaks are available in the spectrum, it may be possible 
to fit a polynomial equation through all the peaks. The spectrum is then corrected by subtracting 
the resulting curved polynomial line from the corresponding spectrum. Among the more 
sophisticated schemes already published for background correction [75-81], the one we chose is 
known as the asymmetric least square (ALS) algorithm. ALS uses a Whittaker smoother series 
for background correction and it is further described in chapter 2 of this dissertation. 
1.9   Multivariate Calibration Algorithms 
The relevance of using multivariate calibration algorithms in analytical chemistry results 
from their ability to extract information from complex samples without the need of previous 
separation procedures. Depending on the complexity of the sample, chemometric algorithms 
used for analytical purposes can be classified into zero-, first-, second- and higher-order 
methods. The progression of orders reflects the power of the algorithm to handle and obtain 
reliable data from matrixes of increasing complexity.  Calibration methods that process first 
order data – first order algorithms – carry with them the first-order advantage, i.e. the ability to 
identify targeted species in the presence of sample concomitants with potential interference. In 
order to provide accurate quantitative information, first-order calibration methods require the 
laborious preparation of extensive calibration data sets containing all sample components with 
potential spectral overlapping.  
A more attractive approach is to handle spectral overlapping with algorithms of second- 
or higher order. Calibration methods capable to provide accurate quantitation of numerous 
targeted species in the presence of un-calibrated interference carry with them the second-order 
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advantage. The application of second-order calibration methods requires second-order or tri-
linear data, i.e. data describing each targeted species with a triad of invariant pure profiles. EEMs 
and total synchronous fluorescence spectroscopy data (TSFS) – i.e. synchronous spectra 
recorded from a multi-component fluorescence mixture at various ∆λ values - fit into the latter 
category. Spectral overlapping in EEM data of OH-PAH was here resolved with N-PLS/RBL, an 
algorithm for processing second order data that combines multi-way partial least-squares (N-
PLS) to the residual bi-linearization procedure (RBL).[1, 82]  The performance of N-PLS/RBL was 
then compared to the well-established multivariate curve resolution-alternating least-squares 
(MCR-ALS) algorithm. The elimination of matrix interference in TSFS data was achieved with 
N-PLS/RBL and with unfolded partial least squares (U-PLS) followed by RBL. A full 
description of N-PLS/RBL, MCR-ALS and UPL/RBL are provided in chapters 3 and 4 of this 
dissertation. 
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CHAPTER 2: ROOM TEMPERATURE FLUORESCENCE 
SPECTROSCOPY OF MONOHYDROXY METABOLITES OF 
POLYCYCLIC AROMATIC HYDROCARBON ON OCTADECYL 
EXTRACTION MEMBRANES 
Calimag-Williams K, Goicoechea HC, and Campiglia AD.  
Analytica Chimica Acta 717 (2012) 100– 109 
 
2.1 Introduction 
Considerable efforts have been made to improve analytical measurements of the 
fluorescence and phosphorescence of compounds on solid materials.[59, 83]   As a result, solid 
surface luminescence analysis is a widely accepted tool in environmental, pharmaceutical, food 
and agricultural science.[84] A variety of solid substrates has been used in solid-surface 
luminescence such as filter paper, silica gel, sodium acetate and polymers. Particularly attractive 
is the use of SPE membranes for the analysis of polycyclic aromatic compounds in water 
samples. [85-89]   The analytical merits include simple experimental procedures for routine 
screening of numerous samples and compatibility with portable instrumentation for field 
analysis. Because of the non-destructive nature of luminescence measurements, can be brought 
to the lab for subsequent elution and confirmation of compounds via high-resolution 
techniques.[90-93]  
The concept was first applied to the analysis of PAH in water samples.[86, 94]  Octadecyl 
extraction membranes were cut in tabs and suspended into aqueous solutions for PAH extraction. 
Depending on the PAH, extraction times varied between one and two hours.  After drying for 
5min the tabs were examined via front-surface RTF. LOD were estimated at the parts-per-billion 
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(ng.mL-1) level.[86, 94] Campiglia’s group extended the concept to room-temperature 
phosphorescence (RTP) analysis. SPE-RTP was applied to the analysis of PAH[87, 95-97], 
polychlorinated biphenyls[97, 98] and polychlorinated dibenzofurans[96, 98]. Bulky glassware and 
vacuum pumps, common to classic SPE lab procedures, were replaced with a syringe kit well-
suited for manual extraction under field conditions. 47mm octadecyl membranes were cut into 
13mm diameter extraction disks to fit into the substrate holder of the spectrofluorimeter. A rapid 
air-drying step, which was accomplished by applying positive pressure to the syringe, removed 
the excess of water from the extraction membrane prior to spectroscopic measurements. The 
same extraction procedure was later applied to the water analysis of PAH via SPE-RTF[99]. Total 
analysis time took less than 10min per sample and provided LOD at the parts-per-billion (pg.mL-
1) level. 
The main disadvantages of SPE-RTP and SPE-RTF for the quantitative analysis of 
polycyclic aromatic compounds in water samples are relatively poor precision of measurements 
and background interference from extraction membranes. The presence of broad, featureless 
excitation and emission bands deteriorates LOD and often interferes with the determination of 
weak emitters at the ng.mL-1 concentration level.[87, 95, 100]  This chapter presents advances in both 
fronts. Signal reproducibility is improved with the aid of a sample holder specifically designed 
for the manual optimization of luminescence signals. Background correction of solid substrates 
is carried out with the aid of ALS, a smoothing algorithm originally devised for baseline 
correction of chromatographic data[101] and often applied to matrix interference in 
chromatographic analysis[102, 103]. To the extent of our literature search, the application of ALS to 
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background reduction from extraction membranes and improvement of SPE-RTF precision of 
measurements has not been reported yet. 
The successful application of our proposition is demonstrated here with the analysis of 
2OH-Flu, 1OH-Pyr, 3OH-B[a]P and 9OH-Phen in synthetic urine samples. Extraction 
membranes serve the dual purpose of sample pre-concentration and solid substrate for RTF 
measurements. This approach – which eliminates elution steps and solvent evaporation prior to 
metabolite determination – provides excellent recoveries via a two-step procedure extremely 
appealing for routine analysis of numerous samples. Recovery values for the studied OH-PAH 
varied from 99.0 ± 1.2% (3OH-B[a]P) to 99.9 ± 0.05% (1OH-Pyr). The new sample holder 
improved the precision of measurements for analytical use. Relative standard deviations (RSD) 
of the studied metabolites varied from 3.5% (2OH-Flu) to 9.5% (9OH-Phe). The application of 
ALS to SPE-RTF improved the LOD by approximately two orders of magnitude. With only 
10mL of urine sample, the LOD of OH-PAH varied from 57pg.mL-1 (2OH-Flu) to 2pg.mL-1 
(1OH-Pyr). 
2.2 Experimental 
2.2.1 Chemicals and Materials 
All solvents were Aldrich HPLC grade. All chemicals were analytical-reagent grade and 
utilized without further purification. Unless otherwise noted, Nanopure water was used 
throughout. 2OH-Flu, 1OH-Pyr and 9OH-Phen were purchased from Sigma–Aldrich. 3OH-
B[a]P was from Midwest Research Institute. All other chemicals were purchased from Fisher 
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Chemical. The Sep-Pak C-18 membranes were purchased from Varian/Agilent. The synthetic 
urine solution was manufactured by RICCA Chemical Company (Arlington, TX) and purchased 
from Fischer Scientific. Its chemical composition mimicked main components of human urine at 
the concentrations found in healthy urine samples.  
Note: Use extreme caution when handling OH-PAH known to be extremely toxic.  
2.2.2 Preparation of stock solution of PAH metabolites 
Stock solutions of PAH metabolites (100 g/mL) were prepared by dissolving 1.0 mg of 
standard in 10 mL of methanol. All stock solutions were kept in the dark at 4 oC. Prior to use, 
stock solutions were monitored via RTF spectroscopy for possible photo-degradation of 
metabolites. Spectral profiles and fluorescence intensities of stock solutions remained the same 
for a period of six months. Working solutions of OH-PAH were prepared daily by serial dilution 
with the appropriate solvent.  
2.2.3 Hydrolysis of urine samples 
Synthetic urine samples (8 mL) were spiked with 1 mL of metabolite stock solution of 
appropriate concentration and equilibrated for 30 min to allow for the interaction of OH-PAH 
with urine components such as urea and various salts. Then 500 L of 0.1 M HCl was added to 
the sample and the mixture was buffered with 500 L of 0.05 M potassium biphthalate sodium 
hydroxide buffer (pH 5.0). The buffered sample was shaken for 30 min at 1400 rpm to allow for 
urine hydrolysis. 
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2.2.4 SPE with octadecyl membranes 
A cork borer with an inside diameter of 10 mm was used to dissect a 47 mm C18 
membrane into 10 mm extraction disks. A 10 mm disk was loaded into a stainless steel filter 
syringe kit (Alltech) and connected to a 10 mL Hamilton syringe (see Figure 2.1). Positive 
pressure was used to force all liquid solutions through the disk.  Prior to sample application, the 
extraction membrane was conditioned with 5 mL of methanol and 5 mL of water. Optimization 
of experimental parameters concerning the retention of PAH metabolites led to the following 
procedure: aqueous metabolite solutions or synthetic urine samples were processed through 
extraction membranes previously conditioned with 5 mL methanol and 5 mL water. Following 
sample extraction, each membrane was sequentially rinsed with 10 mL water and 10 mL of 20% 
methanol/water. Void water was mechanically removed with a 100 mL syringe forcing three 100 
mL volumes of air through the disk. 
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Figure 2.1 Syringe kit for SPE with C-18 membranes. 
2.2.5 Sample holder for SPE-RTF measurements 
The sample holder used for surface substrate measurements is shown in Figure 2.2. Its 
design allows for the optimization of the fluorescence signal via manual rotation of its cover. The 
diameter of the cover indention fits into the opening of the sample compartment’s lid of the 
spectrofluorimeter. The extraction disk is mounted on a rectangular platform and held in place by 
a plate with a circular window for sample excitation. The substrate platform is connected to the 
cover with the aid of a cylindrical rod made hollow for gas purging and sample degassing. The 
height of the platform inside the sample compartment is adjustable by means of a knob placed on 
the rectangular rod of the cover. The cover rod allows for x–y adjustment of the substrate 
position with respect to the excitation beam. Once the excitation beam had been aligned with the 
circular window of the platform, no further optimization was needed. Maximum fluorescence 
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intensities were observed rotating the platform to around 45o in relation to the excitation beam. 
2.2.6 RTF measurements 
Steady state excitation and fluorescence spectra and signal intensities were recorded with 
a commercial spectrofluorimeter (Photon Technology international). The excitation source was a 
continuous-wave 75 W pulsed xenon lamp with broadband illumination from 200 to 2000 nm. 
The excitation and emission monochromators had the same reciprocal linear dispersion (4 nm 
mm−1) and accuracy (±1 nm with 0.25 nm resolution). The gratings were blazed at 300 and 400 
nm, respectively. Detection was made with a photomultiplier tube with spectral response from 
185 to 650 nm. The instrument was computer controlled using commercial software (Felix32) 
specifically designed for the system. Appropriate cut off filters were used to reject straight-light 
radiation and second-order emission. All the spectra are uncorrected for instrumental response.  
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Figure 2.2   Solid-substrate holder for solid-surface room-temperature fluorescence 
measurements. 
2.2.7 Software 
Routines for data pre-treatment and processing were written in MATLAB[104]. Baseline 
routines for emission background correction were adapted from routines previously described in 
the literature for baseline correction of chromatographic data.[105]  Implementation of the ALS 
algorithm included a smoothing parameter equal to 1 × 107, an asymmetry parameter equal to 
0.001, an order of differences in penalty equal to 3 and a single regularization parameter, whose 
value was 1. 
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2.3   Results and Discussion 
The four metabolites chosen for this study were selected as a tentative means of 
comparing our analytical figures of merit (AFOM) of SPE-RTF with previously reported data by 
chromatographic methods. Reported methods usually elute OH-PAH from SPE cartridges with 
milliliter volumes of methanol. Pre-concentration is made via methanol evaporation. Recoveries 
as low as 45–48% have been reported for 3OH-B[a]P[45, 106] one of the metabolites studied here. 
Reported recoveries for the other three metabolites have varied from 62 to 82% (2OH-Flu)[43, 106] 
80 to 99% (1OH-Pyr) [45, 106]  and 93 to 96% (9OH-Phen) [45, 106]. 
2.3.1 RTF analytical figures of merit (AFOM) of OH-PAH in aqueous solutions and 
urine samples 
Figure 2.3 shows the initial survey of room-temperature excitation and fluorescence 
spectra of OH-PAH in methanol/water (1% v/v) solutions. All measurements were made from 
standard (1 × 1 cm) quartz cuvettes filled with undegassed solutions. All spectra were collected 
at 90◦ from the excitation beam using 2 nm excitation and emission band-pass. No attempts were 
made to adjust slit widths for optimum spectral resolution, nor were the spectra corrected for 
instrumental response. The 2 nm band-pass provided signal-to-blank ratios higher than 3 for all 
the studied metabolites at the trace concentration level. No significant changes were observed 
from spectra of OH-PAH in hydrolyzed urine samples or adsorbed on extraction membranes.  
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Figure 2.3  Excitation and fluorescence spectra of OH-PAH metabolites in methanol/water 
(1% v/v) 
 
Table 2.1 summarizes the AFOM of the studied metabolites. All measurements were 
made at the maximum excitation and fluorescence wavelengths of each compound. Each 
calibration curve was built with a minimum of five OH-PAH concentrations. For each 
concentration plotted in the calibration graph, the RTF intensity was the average of three 
determinations taken from three sample aliquots (N = 3). No efforts were made to experimentally 
obtain the upper concentration limit of the calibration curve. The correlation coefficients of the 
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calibration curves were close to unity, indicating a linear relationship between metabolite 
concentration and signal intensity. The linearity was also evaluated by an ANOVA test as 
suggested by IUPAC[107] with satisfactory results. The LOD were calculated using the equation 
LOD = 3 ×SB/m, were SB is the standard deviation of 16 blank determinations and m is the 
slope of the calibration curve. The limits of quantitation (LOQ) were calculated with the formula 
LOQ = 10 × SB/m. The slopes of the calibration curves were obtained with the least squares 
method [108]. The strong fluorescence intensity resulting from the rigid and delocalized -electron 
system of OH-PAH provides LOD and LOQ values at the ng mL−1 concentration level.  
2.3.2 Extraction efficiency of SPE membranes 
The percentages of extraction (%E) were calculated with the formula %E = (IBE – IAE / 
IBE) x 100, where IBE and IAE refer to the fluorescence signals before and after extraction, 
respectively. In all cases, the volume of extracted sample was 10mL. The mass of extracted 
metabolite did not surpass the nominal breakthrough mass (30mg) of extraction membranes [109]. 
Table 2.2 compares %E values obtained from standard solutions to those from hydrolyzed urine 
samples. All values are the averages of three aliquots submitted to the entire extraction 
procedure. Within a confidence interval of 95%, all %E are equivalent to 100% [110]. This fact 
excludes the possibility of matrix interference on the retention of OH-PAH. Similar results were 
obtained with other OH-PAH concentrations within the LDR of Table 2.1. Keeping in mind that 
metabolite elution is not required for the determination of OH-PAH via SPE-RTF, the %E values 
in Table 2.2 correspond to the analytical recovery of the method.  
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Table 2.1   Analytical Figures of Merit of OH-PAH in aqueous and synthetic urine solution 
a Excitation and emission wavelengths. 
 b LDR = linear dynamic range in ng.mL-1 extending from the limit of quantification (LOQ) to an arbitrarily chosen upper linear 
concentration. 
 c Correlation coefficient of calibration curve. .  
d Limit of detection calculated as 3xSB / m; where  SB  is the standard deviation of 6 blank measurements and m is the slope of the 
calibration curve 
.e LOQ defined as 3.3 x LOD.  
PAH 
Metabolite 
1% Methanol – Water Hydrolysed synthetic urine 

exc/ems 
(nm)
a
 
LDR 
b
 
(ng/mL) 
R
2 c
  LOD
d
 
(ng/mL)
 
 
LOQ 
e
  
(ng/mL) 

exc/ems 
(nm)
a
 
LDR 
b
 
(ng/mL) 
R
2 c
     LOD
d
 
(ng/mL)
 
 
LOQ 
e
  
(ng/mL) 
2OH-Flu  273/330 1.20 – 100 0.9999   0.36  1.20 275/328 1.05 – 100 0.9992       0.32 1.05 
1OH-Pyr  344/386 0.30 – 100 0.9999   0.09  0.30  346/385 0.32 – 100 0.9972       0.10 0.32  
3OH-B[a]P  382/434 0.63– 100 0.9947   0.19  0.63 384/430 0.81– 100 0.9940     0.24  0.81 
9OH-Phen  303/384 3.00– 100 0.9984   0.90  3.0  307/384 3.82– 100 0.9946      1.14   3.82  
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Table 2.2  Percent (%) Retention of OH-PAH in C18 membrane from aqueous and 
synthetic urine solutions. 
 
a Concentration are all 50ppb. 
b %Retention = (Ibefore – Iafter)/ Ibefore * 100 
 
2.3.3 Reproducibility of RTF measurements on extraction membranes 
Previous work in our lab studied the deposition pattern of OH-PAHs on extraction 
membrane surfaces [111].  We monitored the fluorescence images of membranes used to extract 
trace concentration levels (ng.mL-1) of OH-PAHs dissolved in 1% methanol/water (v/v) 
solutions. Random deposition patterns of OH-PAHs were observed at all concentration levels. 
The heterogeneous deposition of OH-PAHs on the surfaces of extraction membranes leads to 
poor reproducibility of measurements. One way to improve precision of measurements is to 
irradiate the entire area of the solid substrate via laser excitation with a fiber optic probe [111].  
With commercial spectrofluorimeters equipped with broad band irradiation sources and 
excitation monochromators, one possibility is to opening the excitation slits for complete PAH 
excitation on the extraction membrane.  Unfortunately, opening excitation slits compromises 
 
PAH Metabolite a 
%Retentionb 
1% methanol- water Hydrolysed synthetic urine 
 
2OH-Flu 
 
99.5± 0.93 
 
99.2 ± 0.24 
1OH-Pyr 99.9± 0.05 99.4 ± 1.32 
3OH-B[a]P 99.0 ± 1.19 99.7 ± 0.49 
9OH-Phen 99.4 ± 0.99 96.2 ± 1.35 
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spectral resolution and deteriorates the selectivity of the technique. A practical way to overcome 
this limitation is to using the sample holder in Figure 2.2.  This device optimizes the position of 
the extraction membrane for maximum fluorescence signal.  Maximum intensity results from the 
irradiation of the membrane area with the highest mass of deposited PAH.  
Table 2.3 summarizes the precision of SPE-RTF measurements made with the sample 
holder in Figure 2.2. All extraction membranes were dissected from 47-mm-diameter disks 
belonging to the same commercial lot. Three extraction membranes per metabolite (M1, M2 and 
M3) were used to calculate the average background signals. The same is true for the average 
intensities of extracted metabolites. Standard deviations from single membrane measurements 
were based on signal intensities recorded after three repetitive optimizations of the substrate 
holder position. The relative standard deviations of single membrane measurements were equal 
or lower than 2%, which demonstrates the reproducibility of the signal optimization procedure. 
Fluorescence background was observed from all the examined membranes. It consisted of a 
broad, featureless emission band between 350 and 500nm. Comparison of average background 
values shows considerable intensity variations with excitation and emission wavelengths. The 
same is true with their respective standard deviations. As expected, relatively large background 
variations deteriorate the reproducibility of measurements from extracted metabolites.  
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Table 2.3  Reproducibility study of OH-PAH on C18 membrane  
 
PAH 
Metabolite 
 

exc/ems 
(nm)
a
 
 
IBackground +Sbackground 
c 
(x10
4
) 
  
IOH-PAH +SOH-PAH 
c 
(x10
4
)
 
 
 
Average+standard deviation
d 
(x10
5
) 
  M1 M2
 
      M3    M1
                   
  M2
 
   M3       IBackground                    
  
IOH-PAH  
2OH-Flu 282/330 3.37±0.07 
(2.0)
b
 
3.27±0.07 
     (2.1)
 b
 
3.49±0.05 
(1.4)
 b
 
7.38±0.03 
    (0.4)
 b
 
7.15±0.02 
      (0.3)
 b
 
7.63±0.02 
     (0.3)
 b
 
  0.34±0.01 
        (2.9)
 b 
 
       7.39±0.24 
            (3.2)
 b
 
1OH-Pyr 348/384 4.82±0.02 
(0.4)
 b 
5.08±0.05 
     (1.0)
 b
 
5.28±0.04 
(0.8)
 b
 
  21.2+0.21 
       (1.0)
 b
 
  22.0±0.20 
       (0.9)
 b
 
23.40±0.27 
     (1.2)
 b
 
  0.51±0.02 
        (3.9)
 b
 
        22.0±1.10 
           (5.0)
 b
 
3OH-B[a]P 383/430  2.95±0.02 
      (0.7)
 b
 
3.10±0.04 
     (1.3)
 b
 
3.34±0.04 
(1.2)
 b
 
  13.9±0.31 
       (2.2)
 b
 
  12.6±0.31 
        (2.5)
 b
 
12.34±0.27 
      (2.7)
 b
 
  0.31±0.02 
        (6.4)
 b
 
        12.9±0.83 
            (6.4)
 b
 
9OH-Phen 307/382   2.63±0.04 
     (1.5)
 b
 
2.85±0.06 
     (2.1)
 b
 
2.35±0.01 
(0.l)
 b
 
  2.91±0.03 
        (1.0)
 b
 
   2.39±0.03 
        (1.2)
 b
 
2.67±0.04 
      (1.5)
 b
 
  0.26±0.02 
        (7.7)
 b
 
        2.60±0.26 
           (10.0)
 b
 
 
 
   a Excitation and emission wavelengths 
  b Percent Relative Standard Deviation(% RSD)  = (std dev)/(Iave) x 100  
   c Average values based on three dependent easurements 
  d Average values calculated as [M1 + M2 + M3]x 1/3; standard deviation [s1
2 + s2
2 + s3
2]1/2, where s1, s2, and s3 corresponds to their 
standard deviations   of M1, M2 and M3, respectively 
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2.3.4 Fluorescence background treatment of extraction membranes 
Several attempts were made to decrease the fluorescence background of commercial 
membranes. All attempts assumed the presence of at least one inherent impurity as the source of 
fluorescence background.  These included: (a) “pre-flushing” individual membrane disks with 
the syringe kit using increasing volumes (10, 20 and 30mL) of high purity methanol; (b) 
ultraviolet irradiation of membrane disks for eight hours in a photochemical reactor equipped 
with a total of twelve lamps irradiating at 254nm, 300nm and 320nm, and thin-layer 
chromatography (TLC) of membrane strips using high purity methanol as the mobile phase. All 
these attempts were chosen based on their previous success for background reduction of paper 
substrates [59, 83, 89, 112-114].  
The best background reductions with extraction membranes were obtained via TLC. Each 
chromatographic run was carried out with 34mm x 40mm membrane strips immersed 5mm deep 
in methanol. Visual inspection of membrane strips under an ULTRA-LUM UV-VIS irradiation 
box equipped with 254 and 365nm revealed the maximum migration distance of the fluorescence 
background towards the top of the strip after 10-15min of chromatographic run. The membrane 
disks used for further measurements were cut from the strip area with low fluorescence 
background. Figure 2.4 correlates the background intensity to the number of TLC runs. 
Intensities plotted in the graph correspond to average values calculated from 3 individual 
measurements of 6 membrane disks. The fluorescence background reaches a minimum after 3 
chromatographic runs. Based on this fact, all further experiments were than carried out with 
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extraction disks previously treated with 3 TLC runs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4  Fluorescence background of extraction membranes as a function of 
chromatographic runs with methanol as the carrier solvent. Wavelength measurements 
were the following: exc/em = 282/330nm 2OH-Flu, exc/em = 348/384nm 1OH-Pyr, exc/em 
= 383/430nm 3OH-B[a]P, and exc/lem = 307/382nm 9OH-Phen. 
2.3.5 AFOM of OH-PAH via SPE-RTF 
The SPE-RTF AFOM of the four studied metabolites are summarized in Table 4.4. SPE 
was carried out with 10mL of standards prepared in 1% methanol/water (v/v). For each 
concentration plotted in the calibration graph, the RTF intensity was the average of at least three 
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determinations taken from three extraction disks. The LDR were obtained with a minimum of 
five OH-PAH concentrations. No efforts were made to experimentally obtain the upper 
concentration limits of the calibration curve. It is important to note, however, that the highest 
concentration plotted in each calibration curve did not surpass the breakdown volume of the SPE 
device [99]. The correlation coefficients of the calibration curves and the slopes of the log-log 
plots (data not shown) were close to unity, indicating a linear relationship between OH-PAH 
concentration and fluorescence intensity. Satisfactory results were also obtained by the ANOVA 
test suggested by IUPAC [107]. The RSD at medium linear concentrations were lower than 10%. 
The LOD were estimated at the parts-per-billion to sub-parts-per-billion concentration levels. 
Their comparison to the LOD values in Table 2.1 shows no advantage of pre-concentrating the 
sample prior to RTF. 
Table 2.5 compares the slopes of the calibration curves, blank intensities and their 
standard deviations from aqueous solutions to those obtained on extraction membranes. The 
calibration graphs are shown in Figures 2.5 and Figure 2.6. As expected, sample pre-
concentration provides 10-fold improvements on the slopes of the calibration curves. The main 
reason for the lack of LOD improvements is the higher intensities of blank signals and their 
respective standard deviations on extraction membranes. Better SPE-RTF LOD could have been 
obtained by extracting 100mL volumes of standard solutions, i.e. an alternative with little 
appealing in the screening context of human urine samples. 
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   Table 2.4  RTF Analytical Figures of Merit of OH-PAH on C-18 membrane 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Excitation and emission wavelengths. 
b 
LDR = linear dynamic range in ng.mL
-1
 extending from the limit of quantification (LOQ) to an 
arbitrarily chosen upper linear concentration. LOQ defined as 3.3 x LOD. 
c
 Correlation coefficient of calibration curve. 
 
d 
Limit of detection calculated as 3xS
B
 / m; where  S
B
  is the standard deviation of 6 blank 
measurements and m is the slope of the calibration curve. 
 
 
 
 
 
 
 
 
 
 
 
 
PAH 
Metabolite 

exc
 / 
em
  
(nm) 
a
 
LDR 
b
 R
2 c
 LOD 
d
 
2OH-Flu 282/330 4.33 – 100 0.9987 1.30 
1OH-Pyr 348/384 0.85 – 100 0.9944 0.26 
3OH-B[a]P 383/430 2.35 – 100 0.9984 0.71 
9OH-Phen 307/382 12.83 – 100 0.9969 3.85 
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Table 2.5  Slope and Blank Signals of PAH Metabolites in Aqueous Solution and       
Extraction Membranes 
a Slope of linear dynamic range obtained via the least squares method. 
b Average values based on three individual measurements recorded from extraction 
membranes submitted to the entire extraction procedure. 
 
 
 
 
 
 
 
  
PAH 
Metabolite 
Slopea Ave Blank Intensity + Std. Devb 
H
2
O Membrane
 
 H
2
O (x103) Membrane
  
(x104) 
2OH-Flu 8.6 x 102 7.2  x 103 1.90 + 0.10       3.5 + 0.31 
1OH-Pyr 2.4 x 103 3.2  x 104 0.62 + 0.07       3.9 + 0.29 
3OH-B[a]P 1.6 x 102 1.3  x 104 0.70 + 0.09       3.4 + 0.31 
9OH-Phen 5.8 x 102 2.4 x 103 9.2 + 0.17       2.5 + 0.31 
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Linear   2OH-Flu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Calibration curve of studied metabolites 1% methanol/water (v/v). 
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            Figure 2.6  Calibration of studied metabolites in C18 membrane 
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2.3.6 Background correction via ALS 
The ALS algorithm uses the Whittaker smoother for discrete (time) series, which 
minimizes the function[101]: 
                       pfyQ i  2ii
i
)(                                  (2.1) 
where y is the data (experimental signal), f a smooth trend (or baseline estimation),  
prior weights, and p the asymmetry parameter. The successful implementation of ALS to the 
background correction of extraction membranes was achieved with a smoothing parameter equal 
to 1 x 107, an asymmetry parameter equal to 0.001, an order of differences in penalty equal to 3 
and a single regularization parameter, whose value was 1. Figure 2.7 provides a visual 
demonstration of the clear improvement upon ALS implementation. The background 
intensity(IB) of extraction membranes (see Figure 2.7 )was considerably reduced and so it was 
the standard deviation (SB) of the average background signal. At the maximum fluorescence 
wavelength of 1OH-Pyr (380nm), the IB and SB values before and after ALS treatment were 
4.11x105 ± 0.44x105 counts per second (cps) and 5.4 102 ± 2.09 x 102 cps, respectively.  Table 6 
summarizes the AFOM obtained via SPE-RTF-ALS. Comparison to Table 5 reveals LOD 
improvements ranging from 79.8x (2OH-Flu) to 158.8x (1OH-Pyr). The LOD in Table 2.6 meet 
the expectations for the analysis of OH-PAH in urine samples.  
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Figure 2.7 Fluorescence spectra of 2.5 and 5 ng mL
−1
 of 1OH-Pyr recorded from extraction 
membranes with and without background correction. 
 
 
 
 
 
------   Without background correction 
_____      With background correction 
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Table 2.6  RTF Analytical Figures of Merit of OH-PAH on C-18 membrane with 
background correction 
PAH Metabolite lexc / lem (nm) 
a
  LDR b      R2 c  LOD d  
2OH-Flu 282/330  0.17 – 5.0           0.9939  0.057 
OH-Pyr 348/384 0.006 – 5.0           0.9944 0.0017 
3OH-B[a]P 383/430 0.25 – 5.0           0.9949 0.0075  
9OH-Phen 307/382 0.036 – 5.0           0.9951  0.011 
a Excitation and emission wavelengths.  
b LDR = linear dynamic range in ng.mL-1 extending from the limit of quantification (LOQ) to an 
arbitrarily chosen upper linear concentration. LOQ defined as 3.3 x LOD. 
c Correlation coefficient of calibration curve. 
 d Limit of detection calculated as 3xSB / m; where  SB  is the standard deviation of 6 blank 
measurements and m is the slope of the calibration curve. 
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2.4 Conclusion 
Several features make SPE-RTF spectroscopy a well-suited approach for screening OH-
PAH in urine samples. Its straightforward experimental procedure is attractive for routine 
analysis of numerous samples. The direct determination of OH-PAH on the surface of the 
extraction membrane eliminates the need for subsequent elution steps and provides excellent (~ 
100%) metabolite recoveries. Acceptable precision for analytical work is possible with the aid of 
a substrate holder specifically designed for manual optimization of maximum fluorescence 
signals. Background correction of extraction membranes via ALS provides LOD at the parts-per-
trillion concentration level. With 10mL of urine samples, the LOD varied from 60 (2OH-Flu) to 
2 pg.mL-1 (1OH-Pyr). These values compare favorably to LOD previously reported via other 
methods of analysis, including HPLC[48, 115-118] and RTF- excitation-emission matrix 
spectroscopy of SPE extracts[100].  
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CHAPTER 3: MULTI-WAY PARTIAL LEAST-SQUARES AND RESIDUAL 
BI-LINEARIZATION FOR THE DIRECT DETERMINATIONN OF 
MONO-HYDROXY POLYCYCLIC AROMATIC HYDROCARBONS 
ON OCTADECYL MEMEBRANES VIA ROOM TEMPERATURE 
FLUORESCENCE EXCITATION EMISSION MATRICES 
Goicoechea HC, Calimag-Williams K, and Campiglia AD. Talanta 85(4):1805. 2011 
3.1 Introduction 
The previous chapter reported the first application of SPE-RTF to the analysis of 2OH-
Flu, 9OH-Phen, 1OH-Pyr and 3OH-B[a]P in urine samples .[3] Its successful application was 
made possible with the aid of a sample holder specifically designed to improve the 
reproducibility of measurements on solid substrates. Background correction of extraction 
membranes was carried out with the aid of ALS, a smoothing algorithm originally devised for 
baseline correction of chromatographic data [101] and often applied to matrix interference in 
chromatographic analysis [102, 119].  Recovery values varied from 99.0 ± 1.2% (3OH-B[a]P) to 
99.9 ± 0.05% (1OH-Pyr). The new sample holder improved the precision of measurements for 
analytical use. RSD of the studied metabolites varied from 3.5% (2OH-Flu) to 9.5% (9OH-
Phen).  The application of ALS to SPE-RTF improved the LOD by approximately two orders of 
magnitude. With only 10mL of urine sample, the LOD of OH-PAH varied from 57pg.mL-1 
(2OH-Flu) to 2pg.mL-1 (1OH-Pyr).[3]  The individual determination of any given metabolite in 
the presence of the other three was not attempted due to the strong overlapping we observed 
among their excitation and fluorescence spectra.  
In this chapter, we investigate the analytical potential of EEM data formats for the direct 
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determination of 2OH-Flu, 9OH-Phen, 1OH-Pyr and 3OH-B[a]P without previous 
chromatographic separation. Spectral overlapping of EEMs was resolved via second order 
chemometric analysis. Coupling multidimensional data formats – such as EEMs - with 
chemometric algorithms carrying the second order advantage permits the determination of 
calibrated species in the presence of un-calibrated concomitants, an immensely useful property in 
the present content. EEMs have been traditionally processed by the application of two well-
known algorithms: parallel factor (PARAFAC)[120] or MCR-ALS[121].  Recently attention has 
been paid to alternative second order multivariate calibration algorithms based on latent-
structured methodologies, namely U-PLS/RBL and N-PLS/RBL.[122-125]  PLS-based methods 
appear to be more flexible and provide better figures of merit than their competitors [124, 125].  U-
PLS/RBL was recently applied in our lab to the direct analysis of OH-PAH in SPE extracts 
(methanol solutions).[1] Here, we apply N-PLS/RBL to the analysis of OH-PAH adsorbed on 
extraction membranes and compare its performance to the well-established MCR-ALS 
algorithm. Background correction of extraction membranes was carried out with a new ALS 
procedure adapted to second order data. [101]  Potential interference from naproxen, ibuprofen, 
diclofenac and amoxicillin (see Appendix B for molecular structures) –over-the-counter 
pharmaceutical drugs - was investigated as well. The AFOM obtained via a two-step 
experimental procedure make this approach a well-suited tool for the routine analysis of OH-
PAH in numerous samples. 
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3.2 Theory  
3.2.1 NPLS/RBL 
Different to other second order algorithms, N-PLS/RBL includes concentration 
information only in the calibration step.  The I calibration data arrays and the vector of 
calibration concentrations y (size I×1) are combined to generate regression coefficients v (size 
A×1) and two sets of loadings, namely Wj and Wk of sizes J×A and K×A. J and K refer to 
digitized wavelengths in emission and excitation, respectively.[120] A is the number of latent 
factors, which is usually selected by leave-one-out cross-validation. In the absence of unexpected 
components, the analyte concentration in the test sample can be estimated with equation 3.1:  
    yu = t
T
u v                                                                                          (3.1) 
where tu is the test sample score vector obtained by appropriate projection of the test data 
onto the calibration loading matrices.  
Equation 1 does not apply in the presence of unexpected components in the test sample. 
In those cases, the residuals from the N-PLS modeling of the test sample signals should be 
considered before making predictions. In comparison to typical instrumental noise levels, the 
residuals contained in the matrix Ep (see equation 3.2) should be abnormally large:  
   sp = ||Ep||/(JKI − A)
1/2 = ||Xu − reshape{tu[(Wj| ⊗ |Wk)]}||/(JKI − A)
1/2          (3.2) 
In this equation, “reshape” indicates transforming a JK×1 vector into a J×K matrix and 
|⊗| is the Kathri-Rao operator. In order to handle the presence of unexpected constituents, 
residual bi-linearization resorts to the principal component analysis (PCA) of their contribution 
by minimizing the computed residuals while fitting the sample data to the sum of the relevant 
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contributions. For N-PLS, the sum of contributions is given by equation 3.3: 
Xu = reshape{tu[(Wj| ⊗ |Wk)]} + BunxGunx(Cunx)
T + Eu                               (3.3) 
where matrices Bunx, Gunx and Cunx are obtained by singular value decomposition (SVD) 
of the error matrix Ep: 
     BunxGunx(Cunx)
T = SVD(Ep)                                                            (3.4) 
During the RBL procedure, the loadings are kept constant at the calibration values, and tu 
is varied until the final RBL residual error su is minimized using a Gauss–Newton procedure:  
        su = ||Eu||/(JKI)
1/2                                                                        (3.5) 
Analyte concentrations are then obtained by introducing the values of tu vectors into 
equation 3.1. Due to the use of PCA, retrieved RBL profiles do not necessarily resemble true 
spectra. The aim of RBL is to minimize the residual error term su to a level compatible with the 
degree of instrumental noise. With this in mind, one should always explore an increasing number 
of unexpected components and select the simplest model giving a su value statistically similar to 
the minimum.  
3.2.2 MCR-ALS 
In this algorithm, each matrix data (EEM) is unfolded in a column-wise augmented 
matrix D, instead of forming a three-dimensional data array.  The bilinear decomposition of the 
augmented matrix D is carried out according to the expression: 
      D = C  ST + E                                    (3.6) 
where D rows refer to emission spectra as a function of excitation wavelengths, C 
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columns contain the excitation profiles of the compounds involved in the process and the S 
columns their related emission spectra, and E is the matrix of residuals not fitted by the model. 
The appropriate dimensions of D, C, S and E are thus K(1 + I)J, K(1 + I) F, JF and 
K(1 + I)J respectively (I = number of training samples, J = number of digitized emission 
wavelengths, F = number of extracted factors and K = number of digitized excitation 
wavelengths). Decomposition of D is achieved by iterative least-squares minimization of || E || 
under suitable constraining conditions, i.e. non-negativity in spectral profiles. It is important to 
keep in mind that MCR-ALS requires initialization with system parameters as close as possible 
to the final results. In the column-wise augmentation mode, the use of spectra is required, which 
should be preferentially obtained from pure analyte standards.  
3.2.3 ALS Background Correction Adapted to Second Order Data 
The background matrix F (J×K) is estimated from the data matrix M (J×K), where J and 
K are the number of digitized wavelengths in the emission and the excitation ranges, 
respectively. With this purpose, a B1 (L×J) spline basis matrix along the rows of the M matrix 
and a B2 (M×K) spline basis matrix along the columns of the M matrix are used along with a 
compromise of 10 basis function[126], i.e., L = M = 10. F can be represented as:  
               LMMK
ML,
LJkj, b2b1 af                                               (3.7) 
where aLM is the (L,M) element of an A matrix containing the regression coefficients, 
which can be calculated by minimizing the following cost function: 
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pfyQ K  2)( JKJK
ML,
J                          (3.8) 
In equation 8, y is the experimental signal, f is a smooth trend (the baseline 
approximation), and  are the prior weights. The elements of  should have large values in the 
parts of the signal where it is allowed to affect the estimation of the baseline. Considering the 
choice of the following asymmetric weights: JK = p if JK > fJK and JK = 1 – p if JK  fJK with 0 
< p < 1, positive deviations from the trend will result in weights different from negative 
residuals. Experience shows that starting from   1, and iterating between the two 
computations, quickly and reliably leads to a solution in about 10 iterations. The penalty term in 
equation 8 is defined as follows:  






 
L
2
M
d
2
L
2
L
d
1 ).().( aap                         (3.9) 
where and  are differences of order d calculated for each column (a.L) and row (a.M) 
of A, respectively. If different values are used for the regularization parameter  the penalty may 
have different influence for vertical and horizontal directions.  
3.3 Experimental 
3.3.1 Instrumentation 
Excitation spectra, fluorescence spectra and signal intensities were recorded with a 
commercial spectrofluorimeter and the aid of an in-house sample holder previously described in 
previously described in chapter 2.  
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3.3.2 Reagents 
All solvents were Aldrich HPLC grade. All chemicals were analytical-reagent grade and 
utilized without further purification. Unless otherwise noted, Nanopure water was used 
throughout. 2OH-Flu, 1OH-Pyr, 9OH-Phen and naproxen were purchased from Sigma-Aldrich. 
3OH-B[a]P was from Midwest Research Institute.  All other chemicals were purchased from 
Fisher Chemical.  The Sep-Pak C18 membranes were purchased from Varian/Agilent. The 
synthetic urine solution was manufactured by RICCA Chemical Company (Arlington, TX) and 
purchased from Fischer Scientific. Its chemical composition mimicked main components of 
human urine at the concentrations found in healthy urine samples.  
Note: Use extreme caution when handling OH-PAH known to be extremely toxic. 
3.3.3 Preparation of Stock Solutions 
Stock solutions of PAH metabolites were prepared by dissolving pure standards in 
methanol. Naproxen stock solutions were prepared in methanol. All stock solutions were kept in 
the dark at 4oC.  Prior to use, stock solutions were monitored via RTF spectroscopy for possible 
photo-degradation of metabolites. Spectral profiles and fluorescence intensities of stock solutions 
remained the same for a period of six months. Working solutions of OH-PAH and naproxen were 
prepared daily by serial dilution with methanol. 
3.3.4 Hydrolysis of Urine Samples 
Urine samples were spiked with micro-litters of stock solutions of appropriate 
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concentrations and equilibrated for 30 min to allow for the interaction of metabolites and 
naproxen with urine components such as urea and various salts. Then 500 L of 0.1 M HCl was 
added to the sample and the mixture was buffered with 500 L of 0.05 M potassium biphthalate 
sodium hydroxide buffer (pH 5.0). The buffered sample was shaken for 30 min at 1400 rpm to 
allow for urine hydrolysis. 
3.3.5 Synthetic mixtures of OH-PAHs and spiked urine samples 
All metabolite concentrations were within toxicological relevant levels. Their values were 
adjusted to record EEM with both their true fluorescence fingerprints and fluorescence profiles 
with significant spectral contributions from fluorescence background and instrumental noise. 
Validation set #1 consisted of six synthetic mixtures (S1 – S6) containing the four OH-PAH at 2 
to 4ng.mL-1 final concentrations in methanol-water (1% v/v). Validation set #2 consisted of six 
urine samples (U1 – U6) previously spiked with the four OH-PAHs at 2 to 4ng.mL-1 final 
concentrations.  Validation set # 3 consisted of three urine samples (UN1 – UN3) previously 
spiked with the four OH-PAH at 2 to 4ng.mL-1 final concentrations and naproxen at either 0.2 or 
0.5g.mL-1 final concentration. Naproxen concentrations include the usual values found in urine 
samples from patients taking this anti-inflammatory drug.  
3.3.6 SPE  
SPE was carried out with the syringe kit shown in Figure 2.1 (from Chapter 2 of this 
dissertation). Positive pressure was used to force all liquid solutions through the disk. Prior to 
  63  
 
sample application, the extraction membrane was conditioned with 5mL of methanol and 5mL of 
water. Optimization of experimental parameters concerning the retention of PAH metabolites led 
to the following procedure: aqueous metabolite solutions or synthetic urine samples were 
processed through extraction membranes previously conditioned with 5 mL methanol and 5 mL 
water. Following sample extraction, each membrane was sequentially rinsed with 10 mL water 
and 10 mL of 20% methanol/water. Void water was mechanically removed with a 100mL syringe 
forcing three 100mL volumes of air through the disk. 
3.3.7 Software 
Routines for data pre-treatment and processing were written in MATLAB[104]. Baseline 
routines for matrix background correction were adapted from previously reported routines for 
baseline correction of chromatographic data[101]]. Implementation of the ALS algorithm included 
a smoothing parameter equal to 1 x 107, an asymmetry parameter equal to 0.005, an order of 
differences in penalty equal to 3 and a single regularization parameter equal to 1. MCR-ALS was 
applied with a graphical interface available in the literature[127]. N-PLS/RBL was implemented 
with an integrated chemometric toolbox (MVC2) previously currently available in the 
literature[128, 129].   
3.4 Results and Discussion 
The initial survey of room-temperature excitation and fluorescence spectra on C18 
membranes was carried out by extracting OH-PAH from methanol/water (1% v/v) solutions and 
hydrolyzed urine samples. All spectra were collected using 2nm excitation and emission band-
  64  
 
pass. No attempts were made to adjust slit widths for optimum spectral resolution, nor were the 
spectra corrected for instrumental response. The 2nm band-pass provided signal-to-blank ratios 
higher than 3 for all the studied metabolites at the parts-per-billion (ng.mL-1) concentration level. 
Figures 3.1A-D compare their spectral features recorded from C18 membranes previously used 
to extract methanol/water (1% v/v) solutions. The strong overlapping that exists among the 
spectra of OH-PAH prevents the direct determination of individual metabolites with a single set 
of excitation and fluorescence wavelengths. No significant changes were observed from spectra 
on C18 membranes previously used to extract hydrolyzed spiked urine samples.  
Naproxen, ibuprofen, diclofenac and amoxicillin were selected to modeling the 
pharmacological interference that might occur in the simultaneous determination of co-extracted 
metabolites from urine samples of unhealthy individuals (see Appendix B of this dissertation for 
their molecular structures). Figure 3.2A-D shows their excitation and fluorescence spectra 
recorded from C18 membranes previously used to extract a standard solution of the compound in 
methanol/water (1% v/v).  Fluorescence spectra recorded from spiked and hydrolyzed urine 
samples looked virtually the same. Comparison to Figures 3.1A-D confirms the strong spectral 
overlapping that exists with the four studied metabolites.  
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Figure 3.1   Excitation and Emission Fluorescence spectra of (A) 2OH-Flu ( 100 g L -1, exc 
/em = 282nm/330nm); (B) 1OH-Pyr ( 100 g L 
-1
, exc /em = 348nm/384nm); (C) 3OH-B[a]P 
( 100 g L -1, exc /em = 383nm/430nm); and (D) 9OH-Phen ( 100 g L 
-1
, exc /em = 
307nm/382nm) on extraction membranes.  
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Figure 3.2   Excitation and Emission Fluorescence spectra of (A) Naproxen (10 g L -1, exc 
/em = 284nm/350nm) ; (B) Ibuprofen (100g L 
-1
, exc /em = 280nm/308nm); (C) Diclofenac 
(10 g L -1, exc /em = 282nm/308nm); and (D) Amoxicillin (50 mg L 
-1
, exc /em = 
280nm/310nm) on extraction membranes. 
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3.4.1 EEM background corrections on extraction membranes 
As previously mentioned, the main disadvantage of SPE-RTF for quantitative analysis at 
trace concentration levels is the background interference from extraction membranes. The 
presence of broad, featureless excitation and emission bands deteriorates the LOD and often 
interferes with the determination of fluorescence emitters at the ng.mL-1 concentration level.  
Several attempts have been made in our lab to reduce the fluorescence background of extraction 
membranes[3]. Because the best results were obtained via thin-layer chromatography (TLC), all 
further experiments in this chapter are carried out with extraction disks previously treated via 
TLC. The treatment consists of immersing membrane strips (34mm x 40mm) 5mm deep in 
methanol three consecutive times.  
Figure 3.3A depicts a three-dimensional plot of the RTF-EEM recorded from an 
extraction membrane used to extract 10mL of a hydrolyzed urine sample previously spiked with 
the four studied metabolites. The landscape corresponds to a data matrix M (161x21), which was 
recorded using 5nm (excitation) and 1nm (emission) steps. The excitation and emission 
wavelength ranges were selected to provide a visual comparison of the membrane background 
and the fluorescence signal of the metabolites mixture. The background contribution to the total 
fluorescence of the sample is significant within the entire wavelength ranges of the EEM. The 
matrix background estimation F (161×21) obtained via ALS is shown in Figure 3.3B. The 
estimated matrix was obtained by setting L and M to a value of 10 and the asymmetry parameter 
(p) in equation 8 to 0.005. The subtraction of the F matrix to the M matrix provides the 
background corrected matrix shown in Figure 3.3C. All further experimental EEM were 
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background subtracted generating an ALS matrix within the excitation and emission wavelength 
ranges of interest.  
 
 
 
 
Figure 3.3 (A) RTF-EEM from a C18 membrane used to extract 10 mL of hydrolyzed urine 
sample previously spiked with the four studied metabolites at the ng mL
−1
concentration 
level. Excitation and emission steps = 5 and 1 nm, respectively. (B)Background EEM 
estimated via ALS.(C) EEM resulting from (A) to (B). 
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3.4.2 Second order multivariate calibration 
3.4.2.1 N-PLS/RBL 
The first step in the application of N-PLS/RBL was the assessment of the optimum 
number of calibration factors (A). This was done by resorting to the leave-one-out cross-
validation procedure, which computes the ratios F(A) = PRESS(A<A*)/PRESS(A); where 
PRESS is the predicted error sum of squares, defined as PRESS = ∑(𝑐i,act − 𝑐i,pred)
2, A is a trial 
number of factors and A* corresponds to the minimum PRESS. The number of optimum factors 
was selected as the one leading to a probability of less than 75% and F>1. Since the present 
study was carried out with four metabolites, A was equal to 4.  Because the blank signal was 
eliminated by the pre-treatment procedure, an additional latent variable was not necessary to 
model the variability of the data by N-PLS.  
The next step was to estimate the number of unexpected components in validation sets #2 
and #3 via the post-calibration RBL procedure. This was done by considering the variation of the 
residual (su) in Equation 3.5 as a function of the trial number of unexpected components. The 
stabilization of the residual around the instrumental noise (~ 8.2 x103 counts per second) 
suggested a single unexpected component for urine samples in the absence of naproxen and two 
unexpected components for samples containing naproxen. Figures 3.4A and B show the emission 
and excitation profiles obtained by residual bi-linearization of naproxen and a urine unknown 
component. The good agreement that exists among the predicted and the experimental profiles of 
naproxen demonstrates the success of RBL in extracting the spectral contribution of an unknown 
component from the sample. This ability – which refers to the second-order advantage with an 
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accurate N-PLS algorithm - makes prediction possible with no potential interference from the 
sample.  
 
 
 
Figure 3.4 Fluorescence (A) and excitation (B) profiles obtained by residual bilinearization 
of naproxen (solid trace; blue = predicted; red = experimental) and a urine unknown 
component (broken trace). Excitation and emission bandpass = 2 nm were used to record 
spectra.  
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After correcting the N-PLS scores of validation sets #2 and #3 with the post-calibration 
RBL procedure, we then applied Equation 1 to predict the concentrations the four metabolites in 
all the studied samples. Table 3.1 compares the prediction results to the nominal concentrations 
of the spiked metabolites. The average recoveries for validation set #1 (S1 – S6) were as follows: 
2OH-Flu = 109.7 ± 19.0, 1OH-Pyr = 95.5 ± 7.4, 3OH-B[a]P = 96.7 ± 8.7 and 9OH-Phen = 98.7 
± 11.0. Acceptable predictions were also obtained with validation set #2, i.e. urine samples in the 
absence of naproxen (U1 – U6): 2OH-Flu = 99.5 ± 10.0, 1OH-Pyr = 102.7 ± 4.0, 3OH-B[a]P = 
91.6 ± 8.0 and 9OH-Phen = 92.9 ± 9.0. The worst results were obtained with validation set #3, 
i.e. urine samples containing naproxen (UN1 – UN3): 2OH-Flu = 92.0 ± 10.0, 1OH-Pyr = 81.4 ± 
4.0, 3OH-B[a]P = 86.1 ± 3.0 and 9OH-Phen = 83.9 ± 7.0.  
Figure 3.5A-C provides a visual comparison of RTF EEM recorded from S1 (synthetic 
metabolite mixture prepared in 1% methanol, no naproxen), U1 (synthetic metabolite mixture in 
urine, no naproxen) and UN1 (synthetic metabolite mixture in urine and 200ng.mL-1 of 
naproxen).The poorer accuracy obtained with validation set #3 can be attributed to the relatively 
high fluorescence signal of naproxen, which is present at a ~100-fold higher concentration than 
individual metabolites. Although the contribution of naproxen to the total fluorescence of the 
sample is overwhelming, the prediction results we obtained with set #3 are within ±20% of their 
nominal values. This fact makes them still acceptable for validation of trace analysis in 
biological samples[130].  The complete EEM set for the whole experiment are shown in Appendix 
C. 
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Table 3.1  Predictions obtained when applying N-PLS/RBL to synthetic mixtures (Si), synthetic urines (Ui) and 
synthetic urines spiked with naproxen 200  ng mL
-1
 (UN1), ibuprofen 100 ng mL
-1
 (UN2), diclofenac 10 ng mL
-1
 (UN3), 
amoxicillin 50  ng mL
-1
 (UN4), the four interferences at the previously    mentioned concentrations (UN5).  
 
      Values between parenthesis corresponds to standard deviation for n=3 
Sample 
 
2OH-Flu 1OH-Pyr 3OH-B[a]P 9OH-Phen 
Nominal 
(ng mL-1) 
Predicted 
(ng mL-1) 
Recovery 
     (%) 
Nominal 
(ng mL-1) 
Predicted 
(ng mL-1) 
Recove
ry 
    (%) 
Nominal 
(ng mL-
1) 
Predicted 
(ng mL-1) 
Recovery 
    (%) 
Nominal 
(ng mL-1) 
Predicted 
(ng mL-1) 
Recovery 
   (%) 
S1 1.5 2.1 (0.1) 140.0 2.5 2.2 (0.1) 88.0 2.3 2.5(0.1) 108.7 3.9 3.3(0.1) 84.6 
S2 2.0 2.2 110.0 2.5 2.5 100.0 2.3 2.0 87.0 2.6 2.8 107.7 
S3 2.5 3.1 124.0 2.3 2.3 100.0 1.8 1.9 105.6 3.5 3.2 91.4 
S4 2.3 2.2 (0.1) 95.7 2.0 1.7 (0.2) 85.0 2.2 2.0(0.2) 90.9 3.8 3.5(0.3) 92.1 
S5 2.5 2.4 96.0 2.8 2.9 103.6 2.8 2.7 96.4 3.3 3.4 103.0 
S6 2.6 2.4 92.3 2.9 2.8 96.6 2.4 2.2 91.3 3.0 3.4 113.3 
U1 1.5 1.3 86.7 2.5 2.6 104.0 2.3 2.4 104.3 3.9 3.8 97.4 
U2 2.0 1.9 95.0 2.5 2.6 104.0 2.3 2.0 87.0 2.6 2.8 107.7 
U3 2.5 2.7 108.0 2.3 2.3 100.0 1.8 1.5 83.3 3.5 3.0 85.7 
U4 2.3 2.5 108.7 2.0 2.1 105.0 2.2 1.9 86.4 3.8 3.5 92.1 
U5 2.5 2.6 104.0 2.8 2.7 96.4 2.8 2.6 92.9 3.3 3.0 90.9 
U6 2.6 2.3 88.5 2.9 3.1 106.9 2.4 2.3 95.8 3.0 2.5 83.3 
UN1 2.5 2.6 104.0 2.3 2.0 86.9 1.8 1.6 88.9 3.2 3.3 103.1 
UN2 2.5 2.7 108.0 2.3 2.5 108.9 1.8 2.0 111.1 3.2 3.5 109.4 
UN3 2.5 2.2 88.0 2.3 2.4 104.3 1.8 2.0 111.1 3.2 3.0 93.8 
UN4 2.5 2.6 104.0 2.3 2.1 91.3 1.8 1.9 105.6 3.2 2.9 90.6 
UN5 2.5 2.8 112.0 2.3 2.6 113.0 1.8 2.0 111.1 3.2 3.5 109.4 
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Figure 3.5  RTF EEM recorded from (A) S1 (synthetic metabolite mixture prepared in 1% 
methanol, no naproxen); (B) U1 (synthetic metabolite mixture in urine, no naproxen); and 
(C) UN1 (synthetic metabolite mixture in urine and 200 ng mL
-1 
of naproxen).  Excitation 
and emission steps = 5 and 1nm, respectively. 
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3.4.2.2 MCR-ALS 
The MCR-ALS algorithm was applied to samples from the three validation sets.  
Column-wise augmented data matrices (D) were generated arranging Di matrices corresponding 
to fluorescence (emission) spectra recorded in each EEM. In all cases, non-negativity was 
applied to both excitation and emission profiles.  The number of contributions to each D data 
matrix was determined via singular value decomposition. The computed values were 4, 5 and 6 
for samples in test validation #1, #2, and #3, respectively. The ST-type initial estimates (see 
Equation 6) were built with normalized spectra from pure metabolites and – when appropriate – 
with random vectors for interferents. When resolution results with random estimations were 
unsatisfactory, the MCR spectral profiles of interferents were stored and used as initial 
estimations for subsequent MCR analysis until successful MCR quality parameters were reached. 
The effectiveness of this strategy is demonstrated in Figure 3.6, which shows the MCR-ALS 
spectral profiles retrieved from sample UN1, which contained the four metabolites, an unknown 
urine interferent and naproxen. Their visual comparison to spectra in Figure 3.1 confirms the 
quality of the fitting and the ability to make reasonable predictions by gathering the second order 
advantage.  
The results for the validation samples are summarized in Table 3.2. The average 
recoveries for validation set #1 (S1 – S6) were as follows: 2OH-Flu  = 106.5 ± 16.9, 1OH-Pyr  = 
96.9 ± 7.0, 3OH-B[a]P = 97.5 ± 9.9 and 9OH-Phen = 99.7 ± 11.3. Similar predictions were 
obtained with urine samples (U1 – U6) from validation set #2: 2OH-Flu = 99.4 ± 10.0, 1OH-Pyr 
= 103.8 ± 6.0, 3OH-B[a]P = 90.6 ± 9.7 and 9OH-Phen = 94.2 ± 8.8; and with urine samples with 
naproxen (UN1 – UN3) from validation set #3: 2OH-Flu = 95.4 ± 11.6, 1OH-Pyr = 84.9 ± 3.0, 
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3OH-B[a]P = 84.3 ± 2.3 and 9OH-Phen = 85.3 ± 8.7. The similarity of these averages and their 
standard deviations to those obtained from Table 3.1 confirms the ability of N-PLS/RBL and 
MCR-ALS to provide equivalent results. 
The accuracy of the two models was assessed by comparing the predicted to the nominal 
concentrations of the four metabolites in the three validation sets. The comparison was made 
applying the joint statistical test for the slope and the intercept of the linear regression between 
the nominal and predicted metabolites concentrations. The multivariate model is regarded as 
being accurate if the theoretical values of intercept and slope (zero and unity, respectively) are 
included within the ellipse that describes the mutual confidence region. In order to avoid 
oversizing of the joint confidence region due to the relatively large experimental random errors, 
as well as minimize the possibility to overlook the presence of bias and better estimate the 
variance of the linear regression, we included experimental data Values between parenthesis 
corresponds to standard deviation for n=3 recorded from all the studied samples[131]. Figures 7A 
and 7B  show prediction regions of the global data sets obtained with the N-PLS/RBL and MCR-
ALS algorithms. In the absence of naproxen and within a confidence level of 95%, both 
algorithms provide S and U ellipses that contain the theoretically expected values of the intercept 
(0) and the slope (1). The similar size of ellipses S and U associated to the similar positioning of 
the expected value (0, 1) within the predicted regions allows one to conclude a similar precision 
and accuracy for both algorithms. The same is not true in the presence of naproxen, i.e. UN 
ellipses. The theoretically expected value lies outside the predicted regions of both algorithms. 
This is indicative of the presence of both proportional and constant error.   
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Table 3.2  Predictions obtained when applying MCR-ALS to synthetic mixtures (Si), synthetic urines (Ui) and synthetic 
urines spiked with naproxen 200  ng mL
-1
 (UN1), ibuprofen 100 ng mL
-1
 (UN2), diclofenac 10 ng mL
-1
 (UN3), 
amoxicillin 50  ng mL
-1
 (UN4), the four interferences at the previously    mentioned concentrations (UN5).  
Values between parenthesis corresponds to standard deviation for n=3 
Sample 
 
2OH-Flu 1OH-Pyr 3OH-B[a]P 9OH-Phen 
Nominal 
(ng mL-1) 
Predicted 
(ng mL-1) 
Recovery 
     (%) 
Nominal 
(ngmL-1) 
Predicted 
(ng mL-1) 
Recovery 
    (%) 
Nominal 
(ng mL-1) 
Predicted 
(ng mL-1) 
Recovery 
    (%) 
Nominal 
(ng mL-1) 
Predicted 
(ng mL-1) 
Recovery 
   (%) 
S1 1.5 2.1 (0.1) 133.0 2.5 2.3 (0.1) 92.0 2.3 2.6(0.1) 113.0 3.9 3.4(0.1) 87.2 
S2 2.0 2.2 110.0 2.5 2.6 104.0 2.3 2.1 91.3 2.6 2.9 111.5 
S3 2.5 2.9 116.0 2.3 2.2 95.7 1.8 1.9 105.6 3.5 3.1 88.6 
S4 2.3 2.1 (0.1) 91.3 2.0 1.8 (0.2) 90.0 2.2 1.9(0.2) 86.4 3.8 3.6(0.3) 94.7 
S5 2.5 2.5 100.0 2.8 3.0 107.1 2.8 2.6 92.9 3.3 3.4 103.0 
S6 2.6 2.3 88.5 2.9 2.7 93.1 2.4 2.3 95.8 3.0 3.4 113.3 
U1 1.5 1.4 93.3 2.5 2.6 104.0 2.3 2.4 104.3 3.9 3.6 92.3 
U2 2.0 1.8 90 2.5 2.7 108.0 2.3 2.1 91.3 2.6 2.9 111.5 
U3 2.5 2.8 112 2.3 2.4 104.3 1.8 1.4 77.8 3.5 3.2 91.4 
U4 2.3 2.4 104.3 2.0 2.2 110.0 2.2 1.8 81.8 3.8 3.5 92.1 
U5 2.5 2.7 108.0 2.8 2.6 92.9 2.8 2.7 96.4 3.3 3.0 90.9 
U6 2.6 2.3 88.5 2.9 3.0 103.4 2.4 2.2 91.7 3.0 2.6 86.7 
UN1 2.5 2.7 108.0 2.3 1.9 82.6 1.8 1.5 83.3 3.2 3.3 103.1 
UN2 2.5 2.6 104.0 2.3 2.4 104.3 1.8 2.0 111.1 3.2 3.4 106.3 
UN3 2.5 2.3 92.0 2.3 2.3 100.0 1.8 1.9 105.5 3.2 3.0 93.8 
UN4 2.5 2.7 108.0 2.3 2.2 95.7 1.8 2.0 111.1 3.2 3.1 96.9 
UN5 2.5 2.9 116.0 2.3 2.5 108.7 1.8 2.1 116.6 3.2 3.4 106.3 
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Figure 3.6 MCR-ALS spectral profiles retrieved from sample UN1, which contained the 
four metabolites, an unknown urine interferent and naproxen. Color code as follows: 3OH-
B[a]P = green; 9OH-Phen = yellow; 2OH-Flu = black 
                
   
Figure 3.7  Prediction regions of the global data sets obtained with (A) N-PLS/RBL and (B) 
MCR-ALS B algorithms. 
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3.4.2.3 Analytical Figures of Merit 
All experimental data was gathered from C18 membranes used to extract hydrolyzed 
urine samples previously spiked with OH-PAH. In all cases, the volume of extracted sample was 
10 mL, which is a typical volume for urine analysis of OH-PAH. The mass of extracted 
metabolite did not surpass the nominal breakthrough mass (30mg) of extraction membranes. 
RTF-EEM were recorded at 5nm excitation steps from 220 to 360nm. Sample excitation was 
carried out from longer to shorter wavelengths to reduce the risk of photo-degradation due to 
extensive sample excitation. Fluorescence spectra were recorded at each excitation wavelength 
by scanning the emission monochromator at 1nm steps from 300 to 500nm. All EEM were 
recorded using the same excitation (2nm) and emission (2nm) band-pass.   
Table 3.3 summarizes the analytical recoveries (%R) of the SPE-RTF method and 
compares the AFOM calculated via MCR-ALS and N-PLS/RBL. %R values were calculated 
with the formula %R = (IBE –IAE) x 100, where IBE and IAE refer to the fluorescence intensities 
before and after extraction, respectively. All measurements were made at the maximum 
excitation and fluorescence wavelengths of each compound. Keeping in mind that the adsorption 
of metabolites onto the C18 membrane occurs from an aqueous based matrix (urine) and the 
possibility of matrix interference on the retention of OH-PAH, we first tested their retention from 
standard solutions in water/water (1% v/v) and then compared their values to the extraction of 
spiked urine samples. No significant difference was observed in any of the studied metabolites 
( = 0.05; N1 = N2 = 3)
[132].  
The estimation of the MCR-ALS AFOMs was straightforward and based on the recovery 
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of the pure response profiles resulting from the curve resolution procedure[133]. This approach 
defines sensitivity (SENn) as the slope of the calibration curve obtained from the plot of relative 
fluorescence responses and standard concentrations. The analytical sensitivity (n) was calculated 
as the ratio between the SENn value and the instrumental noise (sx), which was computed from a 
sample of zero concentration taking into account the errors of the slope and intercept of the 
calibration equation[134]. The limit of detection (LOD) was calculated with the equation LOD = 
3.3 sx / SENn.   
The N-PLS/RBL sensitivity was estimated from the following unfolded PLS/RBL 
equations[123]. 
  SENn = 1 / || (Peff
+)T v ||           (3.10) 
where v is the (A1) latent vector of regression coefficients for the PLS model, and Peff is 
a matrix given by:  
  Peff = (Pc,unx   Pb,unx)
T P           (3.11) 
where   is the Kronecker product, P is the (JAA) loading matrix provided by the 
unfolded PLS model, and Pc,unx and Pb,unx are projection matrices calculated as follows: 
  Pc,unx = I – Cunx Cunx
+            (3.12) 
          Pb,unx = I – Bunx Bunx
+            (3.13) 
where the columns of Bunx and Cunx contain the profiles of the unexpected components. 
The n and the LOD were estimated with the same equations as those previously described for 
the MCR-ALS method. It is important to note that, when applying the second order advantage, 
the SENn values from Equation 3.10 become sample-specific. Therefore, the results in Table 3.3 
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should be regarded as average values of the sets of samples we investigated and not as 
representative figures of the whole multivariate method. Although different schemes for 
achieving both the second-order data modeling and the AFOM were employed, comparable 
results were obtained.  
 
Table 3.3 Analytical Figures of Merit of OH-PAH on extraction membranes calculated 
with N-PLS/RBL and MCR-ALS  
 
3.5  Conclusion 
The direct determination of OH-PAH on the surface of the extraction membrane makes 
SPE-RTF spectroscopy a well-suited approach for screening OH-PAH in urine samples. Its 
straightforward experimental procedure eliminates the need for subsequent elution steps and 
provides excellent metabolite recoveries. Comparison of LOD in Table 3.3 to those previously 
reported in chapter 2 (univariate data) shows multivariate values approximately one order of 
Metabolite  Recovery 
(%) 
N-PLS/RBL MCR-ALS  
 SEN 
–1
 
 (ng mL
–1
) 
LOD  
(ng mL
 -1
) 
SEN 
–1
 
 (ng mL
–1
) 
LOD 
 (ng mL
 -1
) 
2OH-FLU  99.2 ± 0.24 22 0.047  0.16  18 0.055 0.18 
1OH-PYR  99.4 ± 1.32 59 0.018  0.06 40 0.025 0.083 
3OH-B[a]P  99.7 ± 0.49 31 0.033  0.11  20 0.050  0.165 
9OH-PHE  96.2 ± 1.35 37 0.028  0.09  25 0.040 0.132 
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magnitude higher. This was somehow predictable due to the effect of unexpected components in 
the multivariate figures of merit, i.e. a more realistic approach to the analysis of OH-PAH in 
human urine samples. It should be noted that the LOD obtained with both multivariate 
algorithms are still comparable to those reported via HPLC methods [[48, 115-118]. Because both N-
PLS/RBL and MCR-ALS are theoretically capable to handle numerous metabolites in the 
presence of unknown interference, their combination to SPE-RTF appears to address the crucial 
issue of spectral overlapping on extraction membranes.    
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CHAPTER 4: ANALYSIS OF POLYCYCLIC AROMATIC 
HYDROCARBON METABOLITES IN URINE VIA SOLID PHASE 
EXTRACTION ROOM-TEMPERATURE SYNCHRONOUS 
FLUORESCENCE SPECTROSCOPY 
4.1 Introduction 
Previous research in our group demonstrated the screening potential of SPE and RTF for 
the analysis of OH-PAH in urine samples. Quantitative determination of metabolites was carried 
out either in the eluent extract
[43, 100]
 or on the surface of the extraction membrane
[3]
. Spectral 
overlapping and matrix interference were eliminated with the aid of EEM data formats and 
chemometrics. In this chapter, we investigate the potential of SFS for the simultaneous analysis 
of OH-PAH urine samples. Originally proposed in an empirical manner for the forensic analysis 
of oil spills
[135-138]
, the theory of synchronous RTF spectroscopy was introduced by Vo-Dinh
[139]
 
and further developed for the environmental analysis of poly-aromatic compounds
[66, 140]
. To the 
extent of our literature search, only a few articles exist on the SFS analysis of OH-PAH in urine 
samples.  Lamotte and co-workers
[141]
 determined 1OH-Pyr on the surface of solid substrates 
(ENVI-Disk
TM
C18) previously immersed in urine samples. LOD at the parts-per-billion level 
were obtained after 30 min of substrate immersion. The simultaneous determination of other OH-
PAH was not attempted. Multiple metabolite determination via SFS in urine samples was first 
reported for the analysis of 1OH-Pyr, 2OH-naphthol and 9OH-Phen
[142]
. Metabolites were liquid-
liquid extracted with n-hexane and determined in the presence of -cyclodextrin (CD). The 
sensitizing effect of CD provided LOD at the 10-8 - 10-9 M range.  A similar approach, but 
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using Tween-20 as the sensitizer, was later employed for the detection of 1OH-Pyr, 2OH-Flu, 
9OH-Phen, 1OH-and 2OH-naphthol at the 10
-8
 - 10
-9
 M range.
[143]
   
In this chapter, 2OH-Flu, 1OH-Pyr, 6-hydroxychrysene (6OH-Chry), 3OH- and 4OH-
B[a]P are solid-phase extracted on C18 silica cartridges with the aid of a twelve-port vacuum 
manifold. SFS carried out in the methanol eluent provided LOD at the sub-parts-per-billion level. 
To the extent of our literature search, this is the first report on the SFS determination of 6OH-
Chry in urine samples. The same is true for the SFS determination of 3OH- and 4OH-B[a]P 
without previous chromatographic separation.  
4.2 Materials and Methods 
4.2.1 Reagents 
All solvents were Aldrich HPLC grade. All chemicals were analytical-reagent grade and 
utilized without further purification. Unless otherwise noted, Nanopure water was used 
throughout. 2OH-Flu, 1OH-Pyr, 6OH-Chry, creatinine, amoxicillin, diclofenac, ibuprofen and 
naproxen were purchased from Sigma-Aldrich. 3OH-B[a]P and 4OH-B[a]P were from Midwest 
Research Institute.  All other chemicals were purchased from Fisher Chemical.  The Sep-Pak 
C18 cartridges were purchased from Waters (Milford, MA). The synthetic urine solution was 
manufactured by RICCA Chemical Company (Arlington, TX) and purchased from Fischer 
Scientific. Its chemical composition mimicked main components of human urine at the 
concentrations found in healthy urine samples. Real human urine was collected randomly from 
healthy individual volunteers. 
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Note: Use extreme caution when handling OH-PAH known to be extremely toxic. 
4.2.2 RTF measurements 
Excitation spectra, fluorescence spectra and signal intensities were recorded with a 
commercial spectrofluorimeter and the aid of an in-house sample holder previously described in 
chapter 2. The collection of synchronous fluorescence spectra were carried out by pouring 
liquids samples into standard (1x1 cm) quarts cuvette. Otherwise noticed, fluorescence was 
collected at 90
o
 angle from excitation using a wavelength off-set equal to 5 nm and an 
excitation/emission band-pass of 1 nm. 
4.2.3 Preparation of stock solutions 
Stock solutions of OH-PAH were prepared by dissolving pure standards in methanol. 
Stock solutions of amoxicillin, diclofenac, ibuprofen and naproxen stock were prepared in 
methanol and kept in the dark at 4
o
C until further use. Prior to dilution, stock solutions were 
monitored via RTF spectroscopy for possible photo-degradation of metabolites. No changes on 
spectral profiles and fluorescence intensities were observed for a period of six months. Working 
solutions of OH-PAH and pharmaceutical drugs were prepared daily by serial dilution with 
methanol. 
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4.2.4 Hydrolysis of urine samples 
Urine samples were spiked with micro-litters of stock solutions of appropriate 
concentrations and equilibrated for 30 min to allow for the interaction of metabolites and 
naproxen with urine components such as urea and various salts. Then 500 L of 0.1 M HCl was 
added to the sample and the mixture was buffered with 500 L of 0.05 M potassium biphthalate 
sodium hydroxide buffer (pH 5.0). The buffered sample was shaken for 30 min at 1400 rpm to 
allow for urine hydrolysis. 
4.2.5 Solid-phase extraction of urine samples 
SPE was carried out with a Visiprep 12 port vacuum manifold (Supelco). Urine samples 
were processed through a Sep-Pak Plus SPE cartridge pre-conditioned with 10 mL of methanol 
and 10 mL of buffered water (pH = 5). The cartridges were sequentially washed with 10 mL of 
buffered water (pH=5) and 5% methanol/water.  Without letting the cartridges to dry, OH-PAHs 
were eluted with 3mL of pure methanol.  
4.3 Results and Discussion 
4.3.1 Efficiency of SPE procedure 
The efficiency of SPE was investigated in two steps, which monitored the retention and 
the eluting efficiency of the solid sorbent and methanol, respectively. The percentage of retention 
(%R) was calculated according to the formula: 
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               %R = (I1 – I2) x 100                                               (4.1) 
Where, I1 and I2 refer to the fluorescence intensity of the solution before and after retention, 
respectively. 
 Keeping in mind that the adsorption of OH-PAH onto the solid sorbent occurs from an 
aqueous-based matrix (urine) and the possibility of matrix interference on the retention of OH-
PAH, their retention was first tested from standard solutions in water (methanol/water 0.05% 
v/v) and then compared their values obtained from the extraction of spiked urine samples. Each 
OH-PAH concentration used in these studies was within the corresponding linear dynamic range 
of the calibration curve. 
 The eluting efficiency (%E) of methanol was obtained from the following equation: 
                                           %E = (mE /mR) x 100                                           (4.2) 
where mE and mR refer to eluted and retained mass of OH-PAH, respectively. The mass of eluted 
metabolite was calculated multiplying the volume of eluted methanol (VE) by the concentration 
of metabolite in the eluted solvent (CE). The experimental values of the eluted concentrations 
were obtained from the calibration curves of the metabolites in methanol. The mass of retained 
metabolite was calculated from the product VS x CS x (%E), where VS and CS refer to the volume 
and concentration of the standard processed through the cartridge, respectively.  
These calculations required the previous knowledge of the fluorescence characteristics of 
OH-PAH in water, methanol and urine. Preliminary studies in this direction were then 
undertaken by carrying out a spectral survey of the studied metabolites in the three types of 
liquid media.  All spectra were recorded using the same excitation and emission band-pass 
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(2nm). No attempts were made to adjust slit widths to optimize spectra resolution, nor were the 
spectra corrected for instrumental response. The 2nm band-pass provided satisfactory signal-to-
background ratios (> 3) for all the studied metabolites at the ng.mL
-1
 concentration level. Figure 
4.1 summarizes the spectral features of the studied metabolites in the three types of media. 
Although fluorescence intensities varied considerably with the liquid environment, the spectral 
profiles of the studied metabolites remained virtually the same in the three types of media. This 
fact provided a single set of maximum excitation (exc) and emission (em) wavelengths per 
metabolite.  
Table 4.1 summarizes the RTF AFOM of the studied metabolites in methanol/water 
0.05% v/v, and hydrolyzed synthetic urine, and pure methanol samples.   Working solutions were 
prepared from intermediate stock solutions by serial dilution with the appropriate solvent - i.e., 
either methanol/water (0.05% v/v) or methanol – or synthetic urine.  Fluorescence measurements 
were made at the exc/em of each compound. Each calibration curve was built with a minimum 
of five metabolite concentrations. For each concentration plotted in the calibration graph, the 
RTF intensity was the average of at least three determinations taken from three sample aliquots. 
No efforts were made to experimentally obtain the upper concentration limit of the calibration 
curve. The main reason for this was that 50 and 100 ng/mL, i.e., the highest concentrations tested 
in these studies, are already at the highest concentration ranges of OH-PAH typically found in 
urine
[115, 116, 144, 145]
. It is important to note, however, that 50 and 100 ng/mL did not surpass the 
breakdown volume of the SPE device
[146]
. The correlation coefficients of the calibration curves 
were close to unity, indicating a linear relationship between OH-PAH concentration and 
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fluorescence intensity. Within the LDR, the (RSD at medium concentrations were lower than 
2%. The LOD were calculated using the equation LOD = 3 x SB/m, where SB is the standard 
deviation of 16 blank determinations and m is the slope of the calibration curve. The LOQ were 
calculated according to the formula LOQ = 10 x SB/m. The m values were calculated via the least 
squares method
[147]
.  At the LOQ concentration levels, the RSD of fluorescence measurements 
varied between 5 and 7%, allowing us to make precise measurements at low-ppb concentration 
levels. 
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Table 4.1  RTF analytical figures of merit of OH-PAH in methanol/water, hydrolysed synthetic urine and methanol 
OH-PAH 
ex/em
a Methanol/water (0.05% v/v) Hydrolysed synthetic urine Methanol 
LDR
b 
R
2c
 LOD
d 
LOQ
e 
LDR
b 
R
2c
 LOD
d 
LOQ
e 
LDR
b 
R
2c
 LOD
d 
LOQ
e 
2OH-Flu 278/328 1.60 - 50 0.9999 0.48 1.58 1.47 - 50 0.9999 0.44 1.47 1.33 – 50 0.9997 0.40 1.33 
6OH-Chry 270/381 0.90 -  50 0.9954 0.27 0.90 0.90 -  50 0.9954 0.26 0.87 0.60  - 50 0.9964 0.18 0.60 
1OH-Pyr 348/387 0.30 - 50 0.9999 0.09 0.30 0.32 - 50 0.9972 0.10 0.32 0.23  - 50 0.9983 0.07 0.23 
3OH-B[a]P 382/432 0.63 - 50 0.9947 0.19 0.63 0.81 - 50 0.9933 0.24 0.81 0.18 -  50 0.9998 0.054 0.18 
4OH-B[a]P 372/421 4.85 - 50 0.9911 1.45 4.85 4.67 - 50 0.9991 1.40 4.67 0.30 - 50  0.9977 0.09 0.30 
a Maximum excitation and emission wavelength in nm. 
b Linear dynamic range in ng/mL. 
c Correlation coefficient of calibration curve.  
d Limit of detection (ng/mL) is calculated from 3 x standard deviation (Sb) of 16 blank measurements divided by slope (m) of 
the calibration curve.  
e Limit of quantification (ng/mL) is calculated from 10 Sb /m. 
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Figure 4.1 Excitation and Emission Spectra of  (A) 100 ng.mL
-1  
2OH-Flu, (B) 50 ng.mL
-1  
6OH-Chry, (C) 20 ng.mL
-1 
1OH-Pyr (D) 100 ng.mL
-1 
4OH-B[a]P , and 20 ng.mL
-1
 3OH-B[a]P in different media at excitation and emission band-
pass = 2nm/2nm. 
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Table 4.2 summarizes the figures of merit of the SPE procedure obtained with 10mL of 
sample and 3 mL of eluting solvent (methanol). The choice of 10mL sample volume corresponds 
to the lowest end of the urine volume range (10 – 250mL) found in the literature [46, 144, 148, 149]. 
The volume of eluting solvent was optimized previously in our laboratory 
[100, 150]
. Metabolites 
were spiked into the urine matrix 24 h prior to analysis. The spiked samples were submitted to 
acidic hydrolysis and then extracted via SPE. The percentages of overall recoveries (%OR) were 
calculated as the product of %R and %E, i.e. %OR = %R∙%E. 
The standard deviations of the overall recoveries (SOR) were based on three independent 
repetitions of the entire SPE procedure and were calculated according to the formula: 
SOR/OR = [(SR/%R)
2
 + (SE/%E)
2
]
1/2 
    (4.3) 
where SR and SE are the standard deviations of %R and %E, respectively 
[100]
. Within a 
confidence interval of 95% (N=3), the overall recoveries in methanol-water standards and 
synthetic urine samples were the same. This agreement shows no matrix interference on the 
extraction of metabolites from synthetic urine samples.
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Table 4.2  Figures of merit for the optimized SPE procedure in aqueous and urine samples 
a
 The final concentrations of spiked samples are 50 ng.mL
-1
 for , 2OH-Flu, and 6OH-Chry and 20 ng/mL for 1OH-Pyr,  
   3OH-B[a]P, and 4OH-B[a]P 
b
 % Standard deviation of % retention efficiency 
c
 % Standard deviation of % elution efficiency. 
d
 % Standard deviation of % overall efficiency. 
e
 texp – t value calculated for experimental measurements according to 87. ttab = 2.78 (α = 0.05; N1 = N2 = 3). 
 
 
OH-PAH % Retention (R) 
R ± SR 
% Elution Efficiecy(E)  
E ± SE 
% Overall Recovery (OR) 
OR ± SOE 
 
texp 
H2O/CH3OH Urine H2O/CH3OH Urine H2O/CH3OH Urine 
2OH-Flu 99.91 ± 0.10 99.79 ± 0.28 99.26 ± 1.78 95.74 ± 2.88 99.17 ± 1.79 95.53 ± 3.02 1.838 
6OH-Chry 98.70 ± 0.65 98.85 ± 0.30 99.80± 1.40 100.0 ± 1.80 98.50±  1.11 98.85 ± 1.65 0.305 
1OH-Pyr 99.29 ± 0.23 99.55 ± 0.38 89.10 ±1.32 88.51 ± 0.95 88.46 ± 1.49 88.11 ± 1.13 0.331 
4OH-B[a]P 96.65 ± 0.24 94.18 ± 1.90 86.15 ± 1.38 89.0 ± 1.9 0 83.26 ± 1.12 83.82 ± 3.60 0.467 
3OH-B[a]P 99.03 ± 0.32 99.63 ± 0.12 99.18 ± 1.44 99.80 ± 1.04 98.22 ± 1.48 99.43 ± 1.05 1.179 
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4.3.2 Synchronous RTF Spectroscopy of OH-PAH 
Constant energy synchronous excitation refers to varying simultaneously both the 
excitation (0) and the emission () wavelengths while keeping constant a wavelength interval 
(0) between them. Along with the optimization of excitation and emission band-pass, 
the judicious choice of the  parameter usually leads to both spectral profile simplification and 
improvement of spectral resolution.[30, 66, 135-138, 151, 152] The most intense synchronous signal of 
each metabolite was observed by recording its fluorescence spectrum at max = em - exc, i.e., a 
wavelength interval equal to the difference between its maximum emission and excitation 
wavelength.  The resulting spectra are shown Figure 4.2. Unfortunately, the overlapping among 
the synchronous spectra of the five metabolites prevented the accurate determination of each 
metabolite at its max. An example of the observed interference is shown in Figure 4.3 for 3OH-
B[a]P.  The higher intensity of the synchronous peak (433nm) of 3OH-B[a]P in the synthetic 
mixture results from the fluorescence contribution of 4OH- B[a]P.  It should be noted that 
narrower excitation and emission band-pass were attempted but no success on spectral 
overlapping was achieved.      
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Figure 4.2  Synchronous fluorescence spectra of OH-PAH at optimum Δλ. Slit width: 1/1; step size: 1 nm. (A) 1OH-Pyr; 
Δλ= 41nm; 20ng.mL-1 (B) 2OH-Flu; Δλ= 61nm; 50ng.mL-1 (C) 3OH-B(a)P; Δλ= 54nm; 20ng.mL-1  (D) 4OH-B(a)P; Δλ= 
48nm; 50ng.mL
-1
  (E) 6OH-Chr; Δλ= 108nm; 50ng.mL-1.   
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Figure 4.3 Synchronous fluorescence spectra of pure 20ng.mL
-1
 3OH-PAH () and 
20ng.mL
-1
 3OH-PAH in OH-PAH mixture (----) in methanol at optimum Δλ = 54nm, 
exc/ems bandpass 2nm/2nm. (Note: mixture contains 20ng.mL
-1 
3OH-B(a)P; 20ng.mL
-1
  
1OH-Pyr; 50ng.mL
-1
 2OH-Flu; 50ng.mL
-1
 4OH-B(a)P; 50ng.mL
-1
 6OH-Chry)  
 
The best case scenarios were observed upon synchronous excitation with relatively small 
wavelength offsets.  values smaller that 10nmproduced single fluorescence peaks for all the 
studied metabolites with narrow full-width at half maxima.  The best compromise between 
spectral resolution and fluorescence intensity was obtained with values of 7 and 5nm. The 
optimization of excitation /emission band-pass provided the best results with 2/2nm ( = 7nm) 
and 1/1nm (= 5nm) and. The resulting spectra recorded from metabolite mixtures in methanol 
are shown in Figure 4.4.  
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Figure 4.4 Synchronous fluorescence spectra of OH-PAH mixture in methanol at different 
offsets (∆)  and Excitation/Emission bandpass. (Note: mixture contains 20ng.mL-1 3OH-
B(a)P; 20ng.mL
-1 
1OH-Pyr; 50ng.mL
-1
 2OH-Flu; 50ng.mL
-1
 4OH-B(a)P; 50ng.mL
-1
 6OH-
Chry)  
 
Table 4.3 reports the AFOM obtained with synthetic urine samples via SPE-SFS. 
Calibration curves were built with spiked samples submitted to the entire experimental 
procedure. Signal intensities plotted in the calibration graphs corresponded to the averages of 
three individual determinations taken from three independently spiked samples. LDR, RSD, 
LOQ and LOD were calculated as those reported in Table 4.1. Comparison of LOD and LOQ 
values in Table 4.3 clearly show the advantage of using  = 7nm and excitation/emission band-
pass = 2/2nm.  
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    Table 4.3  Analytical figures of merit of OH-PAH in methanol via SPE-SFS obtained from synthetic urine samples 
a Maximum synchronous fluorescence wavelength in nm. 
b Linear dynamic range in ng/mL. 
c Correlation coefficient of calibration curve.  
d Limit of detection (ng/mL) is calculated from 3 x standard deviation (Sb) of 16 blank measurements divided by slope (m) 
  of the calibration curve.  
e Limit of quantification (ng/mL) is calculated from 10 Sb /m. 
  
OH-PAH 
max
a  = 5nm,  Bandpass = 1nm/1nm   = 7nm,  Bandpass = 2nm/2nm  
LDRb R
2c
 LOD
d LOQe LDRb R
2c
 LOD
d LOQe 
2OH-Flu 324 16.90 - 200 0.9916 5.07 16.9 1.96 - 200 0.9961 0.588 1.96 
6OH-Chry 377 21.57 - 200 0.9987 6.47 21.57 2.62 - 200 0.9980 0.786 2.62 
1OH-Pyr 390 1.79 - 25 0.9977 0.537 1.79 0.23 - 25 0.9968 0.070 0.23 
4OH-B[a]P 418 12.80 - 100 0.9969 3.84 12.80 1.06- 100 0.9944 0.319 1.06 
3OH-B[a]P 430 4.30 - 50 0.9961 1.29 4.30 0.27 - 50 0.9922 0.082 0.27 
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Figures 4.5A and 4.5B compare the SPE-SFS spectra of synthetic and real urine samples 
spiked with the five metabolites. Comparison to spectra in Figure 4.5 clearly shows the lack of 
urine interference.  Figure 4.5C depicts the SPE-SFS spectrum of a real urine sample spiked with 
the studied metabolites and five potential concomitants. Creatinine is a metabolite usually 
present in human urine samples[153]. Naproxen, ibuprofen and diclofenac are non-steroidal anti-
inflammatory drugs [154, 155] and amoxicillin is an antibiotic[156] of frequent use in our society. 
Their presence in the urine sample does not interfere with the SPE-SFS analysis of the studied 
metabolites. 
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Figure 4.5  Solid phase extraction - synchronous fluorescence spectra of OH-PAH mixture in methanol obtained from 
spiked synthetic urine (A), real urine (B) and real urine with additional spiked with pharmaceutical concomitants (C). 
(Note: OH-PAH mixture: 10ng.mL
-1 
3OH-B(a)P; 5ng.mL
-1 
1OH-Pyr; 20ng.mL
-1
 2OH-Flu; 20ng.mL
-1
 4OH-B(a)P; 
20ng.mL
-1
 6OH-Chry; Pharmaceutical concomitants: 200ng.mL
-1 
 naproxen; 10ng.mL
-1
 diclofenac; 100ng.mL
-1
 ibuprofen 
and 50mg.mL
-1
)   
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Baseline resolution of the five metabolites was achieved via first-derivative SFS. First 
derivative spectra were obtained in post-acquisition mode with Origin software (version 9.0).  
Figure 4.6 shows a set of first-derivative SFS spectra recorded from synthetic mixtures of OH-
PAH at various concentration ratios. Table 4.4 reports the AFOM obtained from synthetic urine 
via SPE-first derivative SFS.  Calibration curves, LDR, RSD, LOQ and LOD were calculated as 
those reported in Table 4.3. Comparison of tabulated values shows LOQ and LOD values within 
the same order of magnitude.  
 
 
 
 
 
` 
 
 
 
 
 
Figure 4.6 First derivative solid phase extraction - synchronous fluorescence spectra of 
OH-PAH mixture in methanol obtained from spiked synthetic urine. Note: OH-PAH 
mixture: 10ng.mL
-1 
3OH-B(a)P; 5ng.mL
-1 
1OH-Pyr; 20ng.mL
-1
 2OH-Flu; 20ng.mL
-1
 4OH-
B(a)P; 20ng.mL
-1
 6OH-Chry)  
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Table 4.4  AFOM obtained from synthetic urine via SPE-first derivative SFS. 
 
 
 
 
 
 
aLinear dynamic range in ng/mL. 
bCorrelation coefficient of calibration curve.  
cLimit of detection (ng/mL) is calculated from 3 x standard deviation (Sb) of 16 blank 
measurements divided by slope (m)of the calibration curve.  
d Limit of quantification (ng/mL) is calculated from 10 Sb /m. 
  
OH-PAH Urine ( = 7nm,  Bandpass = 2nm/2nm) 
LDRa R
2b
 LOD
c LOQd 
2OH-Flu 1.00 – 200 0.9961 0.302 1.00 
6OH-Chry 1.10 – 200 0.9980 0.329 1.10 
1OH-Pyr 0.20 – 25 0.9968 0.060 0.20 
4OH-B[a]P 0.51- 100 0.9944 0.153 0.51 
3OH-B[a]P 0.21 – 50 0.9922 0.063 0.21 
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4.4 Conclusion 
Determination of 2OH-Flu, 1OH-Pyr, 6OH-Cry, 3OH- and 4OH-B[a]P in urine samples 
without the need of previous chromatographic separation was successfully accomplished via 
SPE-SFS. Baseline resolution of OH-PAH was made possible with the aid of first-derivative 
SFS. OH-PAH recoveries via SPE-SFS varied from 83% (4OH-B[a]P) to 99% (3OH-B[a]P). 
These values are excellent when compared to the recoveries of chromatographic methods (see 
Table 1.1.). Further comparison shows that the LOD obtained via SPE-SFS are within the same 
order as those obtained via established methodology. An additional advantage of the new method 
appears to be the relatively short analysis time. It should be noticed that analysis times in Table 
1.1 only include instrumental times. The SPE procedure reported here takes approximately 15 
min. The use of a vacuum manifold allowed its straightforward implementation to the 
simultaneous extraction of twelve samples. Considering the additional 3 minutes per sample that 
it took to perform SF measurements of the solid-phase extracts, we were able to analyze 12 
samples of urine in approximately 55 min. This is equivalent to less than 5 min per sample. The 
non-destructive nature of the new method provides ample opportunity for OH-PAH confirmation 
via chromatographic techniques. Under this prospective, the determination of OH-PAH via SPE-
SFS appears to be a useful approach to monitor exposure of large populations to PAH 
contamination.  
  103  
 
CHAPTER 5:  OVERALL CONCLUSION AND FUTURE WORK 
The development of screening methods for the analysis of OH-PAH in urine samples has 
been accomplished with the aid of SPE and RTF spectroscopy. The analytical potential of the 
new methods was evaluated with six metabolites originating from parent PAH included in the 
EPA priority pollutants list. Quantitative determination of 1-hydroxyfluorene, 1-hydroxypyrene, 
6-hydroxychrysene, 9-hydroxyphenanthrene, 3-hydroxybenzo[a]pyrene and 4-
hydroxybenzo[a]pyrene was carried out either in the eluent extract or on the surface of extraction 
membranes. Their direct determination was based on the collection of EEMs and synchronous 
fluorescence spectra. Spectral overlapping of excitation-emission data was resolved with 
multivariate calibration methods. Base line resolution of the six metabolites was accomplished 
via first derivative synchronous fluorescence spectra. Excellent recoveries and competitive LOD 
were obtained for the six model biomarkers.  
SPE followed by SFS in the eluent extract appears to be the simplest approach with the 
shortest analysis time. The use of a commercial vacuum manifold allows its straightforward 
implementation to the simultaneous extraction of twelve samples in approximately 15 minutes. 
Considering the additional 3 minutes per sample that it takes to record synchronous fluorescence 
spectra form the solid-phase extracts, the analysis of twelve urine samples takes approximately 
55 min. This is equivalent to less than 5 min per sample. The non-destructive nature of the new 
method provides ample opportunity for OH-PAH confirmation via chromatographic techniques. 
Under this prospective, the determination of OH-PAH via SPE-SFS appears to be a useful 
approach to monitor exposure of large populations to PAH contamination.  
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Future work in our lab will focus on processing synchronous fluorescence data with 
multivariate calibration methods. Synchronous fluorescence spectra recorded at a single  value 
fit into the category of first-order data. The accurate determination of OH-PAH with first-order 
calibration methods would require the laborious preparation of extensive calibration data sets 
containing all sample components with potential spectral overlapping. A more attractive 
approach is to handle spectral overlapping with second-order calibration methods, i.e., 
algorithms capable to provide accurate quantitation of numerous OH-PAH in the presence of un-
calibrated interference.  
The application of second-order calibration methods requires second-order or tri-linear 
data, i.e. data describing each OH-PAH with a triad of invariant pure profiles. TSF data of OH-
PAH fits into this category because their spectral profiles vary with the  of synchronous 
excitation. Analogous to the concept of an excitation-emission matrix, the complete set of 
synchronous fluorescence spectra as a function of  provides a data array with comprehensive 
information on the TSF of the sample. TSF spectroscopy coupled to second-order multivariate 
calibration methods should prove useful for the direct analysis of multiple metabolites in highly 
complex physiological matrixes. These include epoxides, dihydrodiols, and tetrols of difficult 
HPLC and/or GC-MS determination.   
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APPENDIX A: MOLECULAR STRUCTURES OF THE MAJOR 
ORGANIC COMPONENTS IN HUMAN URINE 
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Figure A.   Major components in human urine 
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APPENDIX B: POSSIBLE CONCOMITANTS IN OH-PAH URINE 
ANALYSIS  
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Figure B.   Possible pharmaceutical concomitant in human urine for OH-PAH analysis 
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APPENDIX C: EEM SPECTRA OF OH-PAH 
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Figure C-1.  EEM calibration spectra of 1OH – Pyr on C18 membrane at excitation and emission band pass 2nm/2nm.  
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Figure C-2.  EEM calibration spectra of 2OH – Flu on C18 membrane at excitation and emission band pass 2nm/2nm. 
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Figure C-3.  EEM calibration spectra of 3OH – B[a]p on C18 membrane at excitation and emission band pass 2nm/2nm.  
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Figure C-4.  EEM calibration spectra of 9OH – PHE on C18 membrane at excitation and emission band pass 2nm/2nm. 
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Figure C-5. Background subtracted validation EEM of all studied metabolites. Concentrations from water mixtures were at the ng/mL
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Figure C-6. Background subtracted validation EEM of all studied metabolites. Concentrations from synthetic urine mixtures were at 
the ng/mL. 
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Figure C-7. Background subtracted validation EEM of all studied metabolites. Concentrations from synthetic urine mixtures with 
interferents were at the ng/mL. 
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